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 ABSTRACT OF DISSERTATION 
 
 
OPIOID-CANNABINOID CODRUGS WITH ENHANCED ANALGESIC AND 
PHARMACOKINETIC PROFILE 
 
The central hypothesis of the dissertation is that “the design and synthesis of a codrug of 
an opiate and a cannabinoid can be achieved which is stable in the gastrointestinal tract 
and shows a superior pharmacological and pharmacokinetic profile when compared to a 
physical mixture of the two parent drugs.” To prove the hypothesis, a series of novel 
codrugs were prepared by conjugation of the opiate drug codeine with ∆9-
tetrahydrocannabinol (∆9-THC), cannabidiol, abn-cannabidiol and an opiate prodrug 3-O-
acetylmorphine with ∆9-THC. Codeine-cannabinoid codrugs were evaluated for analgesic 
activity in the rat after oral administration. The Cod-THC codrug showed greater 
effectiveness as well as prolonged pain management properties as compared to the parent 
drugs. The stability of Cod-THC codrug in aqueous solutions from pH 1-9, in simulated 
gastrointestinal fluids, in brain homogenate and the hydrolysis of the carbonate ester 
linkage in rat plasma suggested that after oral administration, the codrug would be 
absorbed intact from the GI tract and then hydrolyze in the plasma to generate both 
parent drugs.  The enzymes present in rat brain homogenate were incapable of cleaving 
the codrug into the parent drugs.  
The pharmacokinetic profiles of the Cod-THC codrug and an equimolar physical mixture 
of the parent drugs were evaluated in rats. The plasma concentrations of codeine and ∆ 9-
THC were much higher after codrug administration compared to the plasma 
concentrations of these drugs after oral administration of an equimolar physical mixture. 
The parent drugs were also present in the plasma for longer period of time compared to 
 the physical mixture, probably due to the sustained release of the parent drugs from 
codrug in the plasma. The concentrations of codeine and Δ9-THC were much higher in rat 
brain after oral administration of the Cod-THC codrug as compared to brain 
concentrations of these drugs after oral administration of the physical mixture. Thus, the 
design and synthesis of an opiate and a cannabinoid codrug was achieved which was 
stable in the gastrointestinal tract, showed enhanced analgesic effects as compared to the 
parent drugs, and also showed a superior pharmacokinetic profile when compared to a 
physical mixture or the two parent drugs. 
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Chapter 1 
Object of the Study and Literature Review 
 
1.1 Hypothesis 
  
The hypothesis to be tested in this dissertation work is as follows: the design and 
synthesis of a codrug comprising an opiate drug and a cannabinoid drug can be achieved 
which is stable in the gastrointestinal tract, and exhibits a superior pharmacological and 
pharmacokinetic profile when compared to an equimolar physical mixture of the two 
parent drugs. 
 
1.2 Overall Aim 
 
There is a continuing need for analgesic medications that are able to provide high 
efficacy pain relief while providing more favorable pharmacokinetics and reducing the 
possibility of undesirable side effects. Enhancement of the analgesic effect of opioids by 
combination with cannabinoids has been previously described (Cichewicz et al., 1999). 
These opioid and cannabinoid drugs target opioid and cannabinoid receptors, which are 
found throughout the central and peripheral nervous system (Cichewicz et al., 1999; 
Cichewicz and McCarthy, 2002). In addition, these two classes of drugs produce similar 
effects on calcium levels and cyclic AMP accumulation through G protein-mediated 
pathways (Bloom and Dewey, 1978). However, appropriate dosing of these active agents 
to deliver the drug(s) to the site of action, e.g., the brain or spinal column, can be difficult 
because of their differential pharmacokinetics. Therefore, there is a need to devise a way 
of administering opioids and cannabinoids concomitantly to provide a more favorable 
pharmacokinetic profile for optimizing the enhancement of the analgesic effects. 
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1.3 Methodology to be Utilized in this Study 
 
• To synthesize codrugs comprising one opioid molecule, and one cannabinoid 
molecule, both covalently bound via a linker that is capable of cleaving to the 
parent drugs in the body.  The two drugs will be connected by means of a 
cleavable covalent linker (e.g. ester, carbonate, amide, carbamate, etc.), which 
should hydrolyze in vivo to generate the active parent drug entities.  
• To evaluate the chemical and enzymatic stabilities of one of the codrugs, in order 
to determine its stability to hydrolysis in aqueous media over a range of pHs, and 
its stability in simulated gastric and intestinal fluids, rat plasma, and rat brain, 
utilizing a stability-indicating HPLC-UV assay. 
• To provide a codrug with improved drug stability, as well as improved targeting 
of parent drugs to the site of action (central nervous system) as compared to a 
physical mixture of the parent drugs. 
• To provide a codrug with more desirable pharmacokinetic properties, in particular 
for drugs with different physicochemical properties (e.g. differences in lipid 
solubility, water solubility, polarity, etc.). To determine rat plasma and brain 
concentrations of codrug and parent drugs after oral administration of one of the 
codrugs. To determine the bioavailability of the codrug, and to compare these 
properties with those of a physical mixture of the parent drugs after oral and iv 
administration, utilizing an LC-MS/MS analytical methodology.  
• To provide a codrug that has the potential for treating patients in pain with an 
opioid analgesic, that affords prolonged and effective pain management, while at 
the same time providing the opportunity to reduce the side effects, dependence, 
and tolerance that patients usually experience when subjected to prolonged 
treatment with opioids. 
• To provide a codrug which, after oral administration, produces a superior 
analgesic response to pain (acute, chronic and/or cancer-related) as compared to 
the response from a physical mixture of the two parent drugs.  
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1.4 Literature Review  
 
1.4.1 Codrugs/Hybrid Drugs 
 
There are instances in prodrug design where the prodrug molecule incorporates 
two identical or non-identical drugs into a single chemical entity. This is often desirable 
when two synergistic drugs have different physicochemical and pharmacokinetic 
properties, and it is desirous to have the parent drugs released concomitantly at the site of 
action to obtain a synergistic pharmacodynamic effect that is not attainable by delivering 
a physical mixture of the two drugs. Also, one of the drugs in the codrug structure may be 
incorporated to counterbalance the known side-effects associated with the other parent 
drug, or may amplify the pharmacodynamic effect of the other parent drug through an 
action at another biological target. Thus, codrugs can be designed to overcome various 
barriers to drug formulation and delivery, such as poor aqueous solubility, chemical 
instability, insufficient oral absorption, rapid pre-systemic metabolism, inadequate brain 
penetration, toxicity and local irritation. Structurally, a codrug (also known as a mutual 
prodrug, or hybrid drug) comprises two or more different drugs within a single chemical 
entity where the drugs must each contain an appropriate chemical functionality to enable 
them to be connected together, either directly or by means of a cleavable, biolabile 
covalent linker (Hamad et al., 2006). Such codrugs can be either bipartate or tripartate in 
nature (Silverman, 2004) (Fig.1.1). 
 
Thus, a codrug strategy can be useful when: 
 
• Synergistic drugs need to be given concomitantly to act at the same time, either at 
the same or different biological targets. 
 
• The physicochemical properties of two synergistic drugs are not favorable for 
delivery of the two drugs as a physical mixture, but can be improved by chemical 
combination of the two drugs. 
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• Improved pharmacokinetics results from a chemical combination of two 
synergistic drugs compared to those of a physical mixture of the two drugs.  
 
As with prodrugs, the codrug structure can incorporate two drugs joined together 
by linker moieties such as ester, carbonate, amide, carbamate, etc., which are then 
cleaved enzymatically in vivo to release the active drugs at a required site in the body. By 
appropriate structural design of these linkers, it may be possible to control the release 
kinetics of one or both drugs. When the two drugs are chemically combined together, the 
resulting codrug will usually have different physicochemical properties to those of the 
individual parent drugs, which may provide superior properties for delivery of the two 
drugs when compared to delivery of a physical mixture of the drugs (Howard et al., 
2007). 
 
 
 
                          (A)                                                                 (B)                   
 
Fig. 1.1 Examples of bipartate and tripartate codrugs: A) conjugation of a carboxylic drug 
with an alcoholic drug to form a bipartate codrug where the two drugs are connected by 
an ester linkage which cleaves in vivo to release only the two parent drugs; B) 
conjugation of two alcoholic drug molecules via a carbonate ester linker to form a 
tripartate codrug which cleaves in vivo to form the two parent drugs and an equivalent of 
carbonic acid. 
 
An ideal codrug will generate the parent drugs with high recovery rates, and will 
incorporate linkers that give rise to non-toxic linker residues upon in vivo cleavage. There 
may be other advantages in delivering of two drugs as a single chemical entity versus a 
physical mixture. These include, for example, improved chemical stability of the 
formulation (i.e. no chemical interaction of the two parent drugs within the formulation), 
improved metabolic stability (especially with regard to possible protection of either drug 
from high first pass metabolism), as well as improved targeting of drugs to the site of 
DRUG-1 O C
O
DRUG-2 DRUG-1 O C
O
DRUG-2O
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action (e.g., the central nervous system), and more desirable pharmacokinetic properties, 
in particular for drugs with different physicochemical properties (e.g., differences in lipid 
solubility or polarity). 
 
There are also certain disadvantages that are associated with a codrug strategy. 
One disadvantage is that codrugs are usually large molecules with molecular weights that 
are often greater than 500. Thus codrugs with large molecular weights may well violate 
Lipinsky’s rule of five (Lipinski et al., 2001) as favorable molecules for oral or topical 
dosage form development, or for CNS delivery. In addition, by the very nature of their 
structural design, these cleavable molecules may possess poor stability profiles for 
formulation development. Thus, it must be initially established that the codrug is resilient 
enough to withstand the rigors of formulation development, but must not be too stable 
that it will not efficiently cleave to the parent drugs in vivo. 
 
Another important aspect of codrug design is the toxicological significance of 
delivering a codrug to an individual. Since codrugs are novel chemical entities (although 
the parent drugs they generate may or may not be novel), they will have to be treated as 
new xenobiotics by the FDA, as are all new drugs entities that have never been 
previously administered to humans. Thus, there are important toxicological and safety 
issues associated with the development of codrugs as they move toward clinical status. 
 
Several important criteria are required for codrugs to be effective. The codrug 
must be well absorbed and distribution, metabolism and elimination of the codrug should 
be superior to the physical mixture of the parent drugs. Both parent drugs should be 
released concomitantly and quantitatively after absorption, and the maximal effect of the 
drug combination should occur when a simple molar ratio, i.e. 1:1, 2:1, or 3:1, is utilized. 
 
Before designing the codrug, one needs to know the route of administration. 
Routes of administration can be broadly divided into topical, enteral and parenteral 
routes. The topical route has a local drug effect. The drug is directly applied where the 
action is desired, e.g. asthma medications, eye or eardrops, and decongestant nasal 
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sprays. In the enteral route, drug administration involves any part of the gastrointestinal 
tract. The effect is non-local. Sublingual, oral and rectal are all enteral routes. In 
sublingual administration, the drug is placed under the tongue, is rapidly absorbed and 
avoids first-pass metabolism. The first-pass effect term refers to the hepatic metabolism 
of a drug when it is absorbed from the gastrointestinal tract and delivered to the liver via 
the hepatic portal circulation. The greater the first-pass effect, the lower the concentration 
of drug that reaches the systemic circulation. In the oral (p.o., per os) route, the drug is 
swallowed. It passes through the whole gastrointestinal tract. Drugs taken orally are 
usually cheaper than ones administered by any other route, and can easily be self-
administered (minimal invasiveness) by the patient. The disadvantage of oral delivery is 
that the drug has to be absorbed from the gastrointestinal tract and go through the first 
pass effect. Sometimes this route of administration is inefficient because only part of the 
drug may be absorbed; also a significant first-pass effect may occur. In addition, some 
orally administered drugs can cause irritation of the gastric mucosa, and cause nausea and 
vomiting. 
   
The different parenteral routes for drug administration are intravenous, 
intraarterial, intramuscular and subcutaneous, and more rarely, intracerebral (i.e. directly 
into the brain), intraosseous (into the bone marrow), or intradermal (into the skin itself). 
These different parenteral routes are depicted in Fig. 1.2 (Copeland, 2009).  
  
 
 
 
 
 
 
 
 
Fig. 1.2 Parenteral routes of drug administration (Copeland, 2009) 
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Times taken by drugs to show effect in different routes of administration are 
given below: 
 
 
 
 
 
 
 
 
 
 
Note: drugs given orally take more time than any other route to show a 
pharmacological response, but the oral route is considered to be the safest, pain free and 
cheapest method of drug administration. Other routes are used if there is an emergency 
situation where the effect of the drug is needed in seconds (Silverman, 2004).  
 
Several important criteria are required for codrugs to be effective as compared to 
a physical mixture of the parent drugs, or either of the parent drugs alone. The codrug 
must be well absorbed. When a drug enters the body, it encounters a wide range of pHs. 
A drug given orally faces low pHs in the range 1-2 in the stomach, pHs around 4-6 in the 
intestine, and pHs in the range 5-9 in the colon. These pH values vary in the body, 
depending on the presence of an empty stomach or a fed stomach. The pH values 
generally increase after food is ingested. For example, if the pH of the empty stomach is 
around 1-2, then after the food is taken, it will increase to around 2.5-4. If a codrug can 
survive in this pH range and reach the plasma without being hydrolyzed, it can reach the 
plasma intact, and with appropriate design can release the parent drugs after hydrolysis 
by plasma enzymes. The codrug will also be exposed to various enzymes in the 
gastrointestinal tract which may hydrolyze the codrug to release the parent drugs before 
the codrug reaches the systemic circulation. Therefore, important insights can be obtained 
from incubating the codrug with simulated gastrointestinal fluids in in vivo stability 
• intravenous 30-60 seconds 
• inhalation 2-3 minutes 
• sublingual 3-5 minutes 
• intramuscular 10-20 minutes 
• subcutaneous 15-30 minutes 
• rectal 5-30 minutes 
• ingestion 30-90 minutes 
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studies before carrying out more expensive and time-consuming in vivo pharmacokinetic 
studies. These include stability in simulated gastric fluid (SGF) and simulated intestinal 
fluid (SIF). These fluids are specified in the United States Pharmacopeia (USP). The SGF 
components are pepsin (an acidic protease) and NaCl, and the pH is adjusted to 1.2 with 
HCl. SGF simulates stomach fluid and incorporates both acidic and enzymatic hydrolysis 
conditions. The SIF components are pancreatin (a mixture of amylase, lipase and protease 
from hog pancreas) in monobasic phosphate buffer and the pH is adjusted to 6.8 with 
NaOH. SIF mimics the pH and hydrolytic enzymes in the intestine. The main purpose of 
these stability studies is to predict stability of the codrug after oral dosing. The codrug’s 
stability in these two fluids can often be a guide on how to structurally modify the codrug 
to improve gastrointestinal stability. This information helps in optimizing codrug 
bioavailability and prioritization of compounds for subsequent in vivo pharmacokinetic 
studies. 
  
Once the drug reaches the systemic circulation, it encounters a large number of 
hydrolytic enzymes, such as cholinesterase, aldolase, lipase, dehydropeptidase, and 
alkaline and acid phosphatase in the blood. If the drug has affinity for one of these 
enzymes and it has the correct hydrolysable group in an appropriate position in the 
molecule, it can be degraded in the plasma to generate the parent drugs. In a codrug 
strategy, in vitro plasma stability studies are important and help identify a codrug with 
the optimal properties for releasing the active parent drugs after absorption from the g.i. 
tract. Therefore, it is very important to carry out the in vitro plasma stability studies 
before embarking on the in vivo pharmacokinetic study. This will ensure that compounds 
are subsequently investigated in vivo that are most likely to be successful therapeutics 
(Kern and Di, 2008). 
 
Also, both conjugated drugs should be released concomitantly and quantitatively 
after absorption from the gastrointestinal tract. The maximal effect of the combination of 
the two drugs should occur at a simple ratio, i.e. 1:1, 2:1, or 3:1, and the distribution and 
elimination of the codrug should be superior to the physical mixture of the parent drugs 
(Cynkowska et al., 2005). 
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The codrug can exert its action in two different ways. One way is absorption from 
the gastrointestinal tract into the systemic circulation as a single chemical entity followed 
by cleavage in the plasma and release of the two parent drugs. The other way is to reach 
the site of action first, e.g. the brain, and then undergo cleavage to the parent drugs via 
the action of site-specific enzymes present in the target tissue. With regard to brain 
delivery, small codrug molecules with high lipid solubility and a low molecular mass of 
less than 400–500 Daltons will cross the blood-brain barrier (Pardrige, 2001), and such 
codrugs can be designed to contain a linker that can be cleaved specifically by brain 
enzymes. Alternatively, a codrug can be designed in such a way (i.e. molecular weight 
exceeding 500) that it will not be able to cross the blood-brain barrier, but can deliver the 
parent drugs to the brain after release from the codrug in the plasma. 
 
1.4.2 Marketed Codrug 
 
A good example of an effective and marketed codrug is the antibiotic sultamicillin 
(Unasyn Oral), a tripartate codrug of ampicillin and penicillanic acid sulfone (Fig. 1.3) 
(Baltzer et al., 1980; Hartley and Wise, 1982). Ampicillin is a well-known β-lactam 
antibiotic, but suffers from ineffectiveness against resistant bacteria that excrete high 
concentrations of the bacterial enzyme, β-lactamase. β-Lactamase degrades penicillins 
such as ampicillin by hydrolysis of the β-lactam ring with consequent loss of antibacterial 
activity. Subsequent co-administration of a β-lactam antibiotic with a β-lactamase 
inhibitor was utilized as a strategy for treating resistant strains of bacteria. For example, 
the antibiotic Augmentin is a mixture of the β-lactam penicillin, amoxicillin and the β-
lactamase inhibitor, potassium clavulinate (Fig. 1.3). One of the problems of 
administering the two synergistic drugs together (as a physical mixture) is that they may 
not have similar pharmacokinetic profiles, and thus may not arrive at the target site at the 
same time or at the same concentration. The codrug sultamicillin incorporates a labile 
linker, which on hydrolysis by a plasma esterase affords the two synergistic parent drugs 
in equimolar amounts together with a molar equivalent of formaldehyde. 
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Fig.1.3 Sultamicillin codrug and the in vivo hydrolysis products generated from the 
codrug  (Baltzer et al., 1980; Hartley and Wise, 1982). 
 
1.4.3 Codrug for the Treatment of Proliferative Diabetic Retinopathy 
 
The codrug strategy has previously been utilized when the physicochemical 
and/or pharmacokinetic properties of two synergistic drugs are not favorable for delivery 
of the two drugs as a physical mixture, but can be improved by chemical combination of 
the two drugs. For example, 5-fluorouracil (5-FU) is a polar, water-soluble antiviral and 
cytotoxic drug that is rapidly cleared from the vitreous when delivered topically to the 
eye. In a topical drug combination treatment consisting of 5-FU and the lipophilic, water-
insoluble, anti-inflammatory drug, trihydroxy steroid (THS), a codrug strategy was 
utilized which provided a superior sustained release delivery of the two synergistic parent 
drugs for the treatment of diabetic retinopathy (Howard et al., 2005). The individual 
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physicochemical properties of 5-FU and THS are not favorable for sustained release of a 
physical mixture of the two drugs. However, utilizing a codrug approach, the chemical 
combination of 5FU and THS in a 2:1 molar ratio, respectively (for optimal synergistic 
activity) afforded a molecule with greatly improved physicochemical characteristics for 
sustained delivery compared to formulations of the two drugs as a physical mixture 
(Howard et al., 2005). Fig. 1.4 shows the structure of THS, 5-FU and the THS-BIS-5-FU 
codrug. THS was synthesized from Reichstein’s substance S as depicted in Scheme 1.1. 
The 5-FU-THS codrug was synthesized via the intermediacy of a chloroformate 
analogue, as shown in Scheme 1.1 (a) and 1.1 (b).  
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Fig. 1.4 Structures of THS, 5FU and the THS-BIS-5FU codrug 
(Reprinted from Journal of Enzyme Inhibition and Medicinal Chemistry, Howard et al., 
2005, copyrighted by Informa Healthcare, used by permission”) 
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Scheme 1.1: (a) Synthesis of the chloroformate analogue of THS 
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Scheme 1.1: (b) synthesis of THS-BIS-5FU codrug 
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(Reprinted from Journal of Enzyme Inhibition and Medicinal Chemistry, Howard et al., 
2005, copyrighted by Informa Healthcare, used by permission”) 
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Fig. 1.5 Hydrolytic behavior of the THS-BIS-5FU codrug (Reprinted from Journal of 
Enzyme Inhibition and Medicinal Chemistry, Howard et al., 2005, copyrighted by 
Informa Healthcare, used by permission”) 
 
Fig. 1.6 Cumulative release of THS and 5FU from neat pellets containing 2 mg of the 
THS-BIS-5FU codrug in bovine vitreous humor (Reprinted from Journal of Enzyme 
Inhibition and Medicinal Chemistry, Howard et al., 2005, copyrighted by Informa 
Healthcare, used by permission) 
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The 5-FU-THS codrug was designed as a “chemical delivery” system (Howard et 
al., 2005) which joined together the two drugs via a labile linker moiety. The 
physicochemical properties of the codrug were favorable for both formulation as a 
sutured ophthalmic pellet, and for slow dissolution of the codrug pellet in the vitreous 
humor. The labile linker was specifically designed to undergo rapid hydrolysis once the 
codrug pellet had dissolved, providing sustained release of the parent drugs, which was 
dependent on the rate of dissolution of the codrug pellet. Fig. 1.5 illustrates the hydrolytic 
behavior of the codrug. According to the figure, one molar equivalent of the codrug 
produces one molar equivalent of THS, two molar equivalents of 5FU, and two molar 
equivalents of both formaldehyde and carbon dioxide. Another important consideration in 
the design of the 5-FU-THS codrug was the structure of the labile linker. The two drugs 
were linked together via a linker that afforded hydrolysis products that were considered 
to be non-toxic. The pellets containing the THS-BIS-5FU codrug simultaneously released 
THS and 5FU in 0.1 M phosphate buffer, (pH=7.4), human serum and in bovine vitreous 
humor. Fig. 1.6 depicts the release of THS and 5FU from the codrug in bovine vitreous 
humor. The results demonstrate that a neat pelleted THS-5FU codrug can be utilized as a 
sustained release ocular delivery form of the parent compounds, and that the unique 
physicochemical properties of the codrug allow both a slow dissolution and a rapid 
release of the two parent drugs (Fig. 1.6).  
 
1.4.4 Codrug for the Simultaneous Treatment of Alcohol Abuse and Tobacco 
Dependence 
 
Naltrexone (NTX) is a useful drug for the treatment of alcohol abuse (Volpicelli 
et al., 1992), and cigarette smoking is known to be a social cue for alcoholics. Thus, 
many alcoholics are also chronic smokers. Naltrexol (NTXOL) is the active metabolite of 
NTX (Rukstalis et al., 2000; Wang et al., 2001). NTX produces severe gastrointestinal 
effects, has low bioavailability, and is a hepatotoxin. Also, poor patient compliance via 
the oral route is observed, and neither NTX nor NTXOL is deliverable in therapeutic 
concentrations via the transdermal route (Kiptoo et al., 2006). A codrug approach was 
applied to attempt to solve these problems. Hydroxybupropion (BUPOH) is the active 
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metabolite of the orally active smoking cessation agent, bupropion (Zyban) (Cooper et 
al., 1994; Ascher et al., 1995; Sanchez and Hyttel 1999, Slemmer et al., 2000). A 
transdermal NTX-BUPOH or CB-NTXOL-BUPOH codrug should have improved 
transdermal delivery characteristics, lower toxicity, and afford better patient compliance 
than either NTX or NTXOL. This single codrug entity has the potential to treat both 
alcohol and nicotine abusers when delivered transdermally. Fig. 1.7 shows the structure 
of NTX, NTXOL, BUP, BUPOH and the two codrugs of BUPOH covalently linked to 
either NTX or NTXOL.  
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Fig. 1.7 Structures of parent drugs NTX, NTXOL, BUP, BUPOH and codrugs NTX-
BUPOH and CB-NTXOL-BUPOH 
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Scheme 1.2: Syntheses of NTX-BUPOH and CB-NTXOL-BUPOH codrugs humor 
(Reprinted from Journal of Bioorganic and Medicinal Chemistry Hamad et al., 2006, 
copyrighted by Elsevier, used by permission) 
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The syntheses of the two codrugs were achieved by initial formation of a 
chloroformate derivative of BUPOH followed by coupling of this intermediate with NTX 
and NTXOL. The step-wise syntheses of the codrugs are shown in scheme 1.2 (Hamad et 
al., 2006).  
 
In order to determine the stability of the codrugs, hydrolytic studies were carried 
out in isotonic phosphate buffer at pH 7.4 (physiological pH). The results showed that the 
codrugs were susceptible to hydrolysis and produced the parent drugs at physiological 
pH. Table 1.1 summarizes the results of hydrolytic study performed on the two 
synthesized codrugs and the parent drugs. The proposed hydrolytic conversion of the 
NTX-BUPOH codrug to the parent drugs is shown in detail in Fig. 1.8. The NTX-
BUPOH codrug undergoes cleavage of the carbonate bond to generate NTX, and a stable 
cyclic carbamate intermediate of BUPOH, which then undergoes hydrolysis to 
subsequently generate BUPOH. The chemical stability of the NTX-BUPOH codrug was 
studied in isotonic phosphate buffer at pH 7.4 over 4 days. The disappearance of the 
codrug and the appearance of the two parent drugs over time are shown in Fig. 1.9. The 
rate of appearance of NTX was identical to the rate of disappearance of the codrug. On 
the other hand, the rate of formation of BUPOH was found to be slower than the rate of 
disappearance of the codrug, involving the formation of a relatively stable intermediate. 
That intermediate was identified as the 5-membered cyclic carbamate analogue of 
BUPOH (Hamad et al., 2006). 
  
The stability of the carbonate codrug of 6-β-naltrexol and hydroxubupropion was 
also evaluated in Guinea pig plasma after transdermal delivery. Fig. 1.10 illustrates the 
hydrolytic profile of the carbonate codrug (CB-NTXOL-BUPOH) and the time course of 
formation of the two active parent drugs in the plasma. The release of 6-β-naltrexol from 
the codrug was a one-step process, as confirmed by rate of appearance of 6-β-naltrexol 
being the same as the rate of disappearance of the carbonate codrug. The release of 
BUPOH involved the initial formation of the cyclic carbamate analogue of BUPOH, 
which was then converted subsequently to the parent drug, BUPOH. The rate of 
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hydrolysis of the CB-NTXOL-BUPOH codrug in plasma was 3 times faster compared to 
the rate of hydrolysis in isotonic phosphate buffer at pH 7.4 (Kiptoo et al., 2008).  
 
The CB-NTXOL-BUPOH codrug and 6-β-naltrexol were administered 
transdermally to hairless Guinea pigs and the concentrations of the parent drugs in the 
plasma were determined by LC-MS/MS. The plasma concentration profile of the analytes 
following topical application of either CB-NTXOL-BUPOH or 6-β-naltrexol is shown in 
Fig. 1.11. The results showed a fivefold enhancement in the transdermal delivery of 6-β-
naltrexol when given in the form of the codrug. Also, the codrug delivered a significant 
amount of BUPOH to the plasma when administered transdermally. The cyclic carbonate 
intermediate of BUPOH was not detected in the plasma of codrug-treated Guinea pigs. 
The calculated pharmacokinetic parameters for the CB-NTXOL-BUPOH codrug and 6-β-
naltrexol are listed in Table 1.2 (Kiptoo et al., 2008). 
 
 
Table 1.1 Physicochemical Properties of NTX (1), NTXOL(2), BUPOH(4) and the 
carbonate codrugs,  NTX-BUPOH (25) and CB-NTXOL-BUPOH (26) 
  
 
(Reprinted from Journal of Bioorganic and Medicinal Chemistry Hamad et al., 2006, 
copyrighted by Elsevier, used by permission) 
 
 
 
 
20 
 
O
O
N
OH
O
N
O
O
O
O
O
HO
N
OH
O
O
N
O
O
Cl
NHH2C
O
OH
Cl
k1
k1
k4
-CO2
Cl
O
N
O
OH
Cl
O
OH
k3-CO2
rapid, k2
-CO2
O
HN
OH
Cl
rapid
 
 
Fig. 1.8 Hydrolytic behavior of the NTX-BUPOH codrug 
(Reprinted from Journal of Bioorganic and Medicinal Chemistry Hamad et al., 2006, 
copyrighted by Elsevier, used by permission) 
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Fig 1.9 Hydrolytic profile of the carbonate drug hybrid, NTX-BUPOH, in isotonic 
phosphate buffer at pH 7.4 (Reprinted from Journal of Bioorganic and Medicinal 
Chemistry Hamad et al., 2006, copyrighted by Elsevier, used by permission) 
 
Table 1.2 Pharmacokinetic parameters of NTXOL in the Guinea pig after application of a 
gel formulation containing either CB-NTXOL-BUPOH or NTXOL base. (Reprinted from 
European Journal of Pharmaceutical Sciences, Kiptoo et al., 2008, copyrighted by 
Elsevier, used by permission) 
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Fig 1.10 Hydrolytic profile of the carbonate drug hybrid, CB-NTXOL-BUPOH, in 
Guinea Pig Plasma at 37oC (Reprinted from European Journal of Pharmaceutical 
Sciences, Kiptoo et al., 2008, copyrighted by Elsevier, used by permission) 
 
 
 
Fig 1.11 Mean (±S.D.) plasma concentration profiles in guinea pigs after topical 
application of a gel formulation containing either CB-NTXOL-BUPOH or 6-β-Naltrexol 
(control). The dotted line (----) indicates the plasma concentration after the removal of the 
formulation. . (Reprinted from European Journal of Pharmaceutical Sciences, Kiptoo et 
al., 2008, copyrighted by Elsevier, used by permission) 
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1.4.5 L-DOPA Codrugs 
 
Dopamine is deficient in the brains of patients suffering from Parkinson’s disease. 
Unfortunately, dopamine cannot be given as a drug for this disease because it cannot 
cross the blood-brain barrier. L-Dopa is a precursor of dopamine, and is used in the 
treatment of Parkinson’s disease. L-Dopa crosses the blood-brain barrier via facilitated 
transport, and is then converted to dopamine in the brain by the enzyme DOPA 
decarboxylase. For the treatment of Parkinson’s disease, L-Dopa is given in combination 
with a peripheral dopa decarboxylase inhibitor such as carbidopa, to prevent degradation 
of L-Dopa in the systemic circulation. Entacapone is another L-Dopa decarboxylase 
inhibitor, which is currently used with L-Dopa to treat Parkinson patients. Since oral L-
Dopa bioavailability is low, a codrug approach was utilized, by combining L-Dopa and 
entacapone via an ester linkage to improve L-Dopa brain delivery (Fig.1.12). The codrug 
showed stability in aqueous media at different pHs and was hydrolysed to the parent 
drugs in liver homogenate, fulfilling the codrug criteria (Leppanen et al., 2002). 
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    Fig.1.12  L-Dopa ester of entacapone 
 
 
A series of codrugs have also been designed by linking L-Dopa and dopamine 
with antioxidant compounds such as α-lipoic acid, glutathione, caffeic acid, carnosine, 
benserazide and N-acetylcysteine (Stefano et al., 2006 [1]; Stefano et al., 2007; Piera et 
al., 2008; Stefano et al., 2006 [2]; Pinnen et al., 2009). 
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Fig. 1.13 (a) L-Dopa and α-lipoic acid codrug (b)  Dopamine and α-lipoic acid codrug  
 
As shown in Fig.1.13, L-Dopa and dopamine can be linked to α-lipoic acid and 
glutathione via an amide linkage (Stefano et al., 2006). α-Lipoic acid is an effective 
antioxidant. It exists as dihydrolipoate in vivo, which can regenerate (reduce) antioxidants 
such as glutathione, vitamin C and vitamin E (Biewenga et al., 1997; Packer et al., 1995). 
The strained 5-membered ring conformation of lipoic acid contributes to its good 
scavenging activity (Haenen and Bast, 1991). All the four codrugs in Fig. 1.13 showed 
good stability in the gastrointestinal tract and cleaved enzymatically in rat and human 
plasma to release the parent drugs. The prolonged release of L-Dopa showed the 
effectiveness of the L-DOPA codrugs. Codrugs 1 and 2 were used to test antioxidant 
efficacy using superoxide dismutase (SOD) and glutathione peroxidase (GPx) markers. 
These enzymes have a central role in the control of reactive oxygen species (ROS). SOD 
dismutates highly reactive superoxide into oxygen and hydrogen peroxide. GPx reduces 
hydrogen peroxide to water by oxidising GSH. The oxidised form of GSH (GSSG) is 
reduced back to GSH by glutathione reductase, as shown in the equations below: 
 
H2O2 + 2 GSH ---> GSSG + 2 H2O 
GSSG + NADPH + H+ ----> 2 GSH + NADP+ 
 
Codrugs 1 and 2 showed increased GPx activity as compared to L-DOPA alone, 
which could indicate a decreased production of free radicals. Also, these codrugs induced 
decreased activity of SOD as compared to L-DOPA alone, indicating a reduced 
production of superoxide anions.  
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  Similar results were obtained when codrugs of L-Dopa and glutathione were 
constructed with amide linkages (Stefano et al., 2007). Glutathione helps in the 
decomposition of toxic peroxide molecules, protects enzymes by maintaining their SH 
groups in a reduced state, and is also involved in the repair of oxidized iron-sulfur centers 
of the mitochondrial complex. No hydrolysis of these codrugs was observed in 
gastrointestinal fluids and L-DOPA was released in plasma via enzymatic hydrolysis. The 
codrugs also showed an antioxidant effect using SOD and GPx markers (Fig. 1.14). 
 
OH
OH
CO2R'
N
H
OH
N
O
N
H
O
CO2R'
RHN
SH HO
HO
NHR
O
H
N
CO2R'
O
N
H O
H
N CO2R
'
SH
1: R=Ac; R'=Me 2: R=H; R'=H 3: R=Ac; R'=Me 4: R=H; R'=H  
       (a)        (b) 
Fig. 1.14 (a) L-Dopa and Glutathione codrug  (b) Dopamine and Glutathione  codrug 
 
Like glutathione or α-lipoic acid, the other two antioxidants, caffeic acid and 
carnosine, were conjugated with L-Dopa (Fig. 1.15) and assessed by evaluating plasmatic 
activities of SOD and GPx in rats (Piera et al., 2008). These codrugs were devoid of 
significant antioxidant activity, although the literature is full of reports that caffeic acid 
and carnosine act as natural antioxidants with hydroxyl radical-scavenging and lipid-
peroxidase activities. 
 
To overcome the pro-oxidant effects of L-Dopa, the other antioxidants used were 
sulfur containing, such as N-acetyl cysteine (NAC), methionine and bucillamine (Fig. 
1.16).  N-acetylation of cysteine speeds up cysteine absorption and distribution when 
given orally. NAC helps in increasing the intracellular concentration of glutathione via 
elevating intracellular cysteine levels. NAC is rapidly absorbed, enters cells, and is 
rapidly hydrolyzed to cysteine. Methionine is also an intermediate in the synthesis of 
cysteine, and helps PC 12 cells against DA–induced nigral cell loss in Parkinson’s 
disease by binding to oxidative metabolites of dopamine (Grinberg et al., 2005; Offen et 
al., 1996; Martı´nez et al., 1999). Bucillamine is a synthetic cysteine derivative used for 
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the treatment of rheumatoid arthritis (Horwitz, 2003). It contains two thiol groups, which 
makes it a more powerful antioxidant as compared to NAC and methionine. It can be 
easily transported into cells to restore GSH under conditions of oxidative stress and GSH 
depletion (Hammond et al., 2001). 
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Fig. 1.15 Structures of (a) 3, 4-diacetyloxy-L-dopa methyl ester-caffeic acid codrug           
(b) 3, 4-diacetyloxy-L-dopa methyl ester–carnosine codrug 
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Fig. 1.16 Codrugs of L-Dopa linked to cysteine, methionine and bucillamine 
 
Six codrugs were constructed using L-Dopa as one of the parent drugs and 
NAC/methionine/bucillamine as the other parent drug (Stefano et al., 2006 [2]). All the 
codrugs showed good lipophilicity and water solubility for optimal intestinal absorption. 
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The stability study at pH 1.3 and in SGF indicated that the codrugs would be stable 
enough to pass un-hydrolyzed through the stomach after oral administration. At pH 7.4, 
they were stable enough to be absorbed intact from the intestine. In rat and human 
plasma, the codrugs hydrolyzed to release the parent drugs, although the release of L-
Dopa from the codrugs was very slow. Next, the antioxidant efficacy of codrugs was 
evaluated using a chemiluminescent assay. The comparison was made using NAC; all the 
codrugs showed a better antioxidant effect as compared to NAC. The physicochemical 
and pharmacokinetic data showed high levels of L-Dopa in the plasma and brain, even 12 
h after administration. Codrugs 3 and 4 were able to induce a sustained release of L-Dopa 
and dopamine in rat striatum with respect to equimolar doses of L-Dopa. Codrug 4 was 
injected intracerebroventricularly, and it resulted in levels of dopamine in the striatum 
that were higher than those in L-Dopa-treated rats. This indicated that the codrug had a 
longer half-life in brain than L-Dopa (Stefano et al., 2006 [2]). 
  
Benserazide is a Dopa-decarboxylase inhibitor. An L-Dopa codrug with 
benserazide had good lipophilicity as compared to either L-Dopa or benserazide (Fig. 
1.17). The codrug was stable in aqueous buffer solutions. In plasma, the catechol esters 
and amide bonds were efficiently cleaved, releasing the parent drugs in one step (Stefano 
et al., 2006 [2]). 
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Fig. 1.17 Codrug of L-Dopa with benserazide 
1.5 A Codrug strategy in pain management 
 
1.5.1 Opioids and Cannabinoids 
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  Opioid and cannabinoid interaction in the prevention of pain is very significant, 
especially in the case of chronic pain, where higher doses with greater side effects are 
encountered. Combination of these two drug types produced an analgesic effect, even 
with inactive doses of either drug alone, which suggests the possibility of utilizing 
smaller doses yielding fewer side effects and less addiction potential (Cichewicz, 2004). 
In addition, opioids exert their analgesic effect on nociceptive pain while cannabinoids 
are effective in modulating neuropathic pain. Thus, an opioid-cannabinoid codrug might 
be able to cover a broader range of pain. Several articles have been published on the 
interaction of opioids with cannabinoids, which are explained further in this chapter.  
Keeping the interactions between these two classes of analgesics in mind, various codrug 
combinations of opioids and cannabinoids were synthesized in this dissertation work. 
These syntheses are discussed in the next chapter. 
 
1.5.2 Pharmacokinetics and Pharmacodynamics of Opioids 
 
Opioids are compounds having morphine-like pharmacological activity. The term 
opiate refers to any natural or synthetic agent derived from, or structurally related to 
morphine (Thorn, 2009). The endogenous enkephalin peptides and the endorphins are, 
therefore, opioids because they are not structurally related to morphine, but have the 
same pharmacological activity.  
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         Fig. 1.18 Structures of Morphine, Codeine and Endogenous Opioids 
 
Fig. 1.18 shows the structures of morphine, codeine and a selection of 
endogenous opioids. Codeine and morphine are the major pain relief drugs in the opiate 
family. Both drugs are found naturally in the poppy plant, Papaver somniferum, but for 
commercial use, codeine is usually synthesized from morphine, which is more abundant 
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in nature (Thorn, 2009). In addition to their analgesic effects, both drugs have antitussive 
effects and antidiarrheal activity. Side effects include respiratory depression, 
constipation, sedation and addiction. Codeine is a less potent agonist at the mu opioid 
receptor (OPRM1) compared to morphine, and is considered a safer alternative in an 
outpatient setting.  
 
The principal pathways for the metabolism of codeine occur in the liver, although 
some metabolism occurs in the intestine and brain. Approximately 50-70% of codeine is 
converted to codeine-6-glucuronide by the UGT2B7 glucuronyl transferase enzyme.  
Codeine-6-glucuronide has a similar affinity for the mu opioid receptor as codeine. 
Approximately 10-15% of codeine is N-demethylated to norcodeine by CYP3A4 (Thorn, 
2009). Norcodeine also has a similar affinity to codeine for the mu opioid receptor. 
Between 0-15% of codeine is O-demethylated to morphine, the most active metabolite, 
which has 200 fold greater affinity for the mu opioid receptor compared to codeine. This 
metabolic reaction is performed by CYP2D6. Approximately 60% of this morphine is 
glucuronidated to morphine-3-glucuronide (M3G) while 5-10% is glucuronidated to 
morphine-6-glucuronide (M6G). These reactions are principally catalyzed by UGT2B7 in 
the liver. 
 
Opioids exert their antinociceptive effects via interaction with opioid receptors 
(Pan et al., 2008). There are four major opioid receptors, which have already been cloned: 
mu, delta, kappa and nociceptin/orphanin FQ receptors (opioid receptor-like 1[ORL1]) 
(Pan et al., 2008). There is good evidence for the existence of subtypes of mu-, delta- and 
kappa-receptors. These receptors are located in brain and spinal cord tissues and each 
receptor plays a role in the mediation of pain. The mu receptor is morphine-selective and 
is the principal pain-modulating site in the central nervous system. There are two 
subtypes of mu receptor: mu1 and mu2. Subtype mu1 is mainly the analgesic site, while 
subtype mu2 is responsible for respiratory depression. Opioid receptors belong to the G-
protein-coupled receptor (GPCR) superfamily, and are heterodimeric receptors with 
ligand binding and signaling capabilities. These GPCRs possess seven cell membrane-
spanning domains with extracellular ligand binding sites for specific molecules. 
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Interactions with those sites result in modulation of signal transduction pathways 
involving second messengers such as cAMP, inositol phosphate, or calcium, which is 
ultimately translated into cellular responses. Opioid binding can increase calcium ion 
release from intracellular calcium ion stores via activation of the second messenger, 
phospholipase C. 
 
Chronic opiate administration leads to tolerance and a desensitization of opioid 
receptors. In many, but not all instances, a down-regulation of opioid receptors in vivo 
occurs following chronic opioid administration (Rotha et al., 1998). 
 
The expression level of different opioid receptors is influenced by different pain 
conditions. Pain can be broadly divided into two categories: nociceptive pain, in which 
the free peripheral nerve endings are activated by noxious stimuli such as heat, pressure, 
etc.  This is manifested as a kind of constant, dull and aching pain. Neuropathic pain 
occurs as a result of damage to the peripheral or central nervous system. Examples are 
diabetic neuropathy, multiple sclerosis, or spinal cord injury. This pain is often described 
as “burning and tingling”. It is characterized by hyperalgesia (increased painful response 
to noxious stimulus) and allodynia (pain to a previously non-noxious stimulus) (Pan et 
al., 2008).  
 
Pain is inadequately managed with currently available drugs, especially for 
patients suffering with chronic pain conditions such as cancer or AIDS. Opioids are 
considered to be most effective for treatment of nociceptive pain but show little or no 
effect in neuropathic pain. In the case of nerve injury, or in diabetic neuropathy, mu 
receptor expression is reduced in the spinal dorsal horn, which reduces the 
antinociceptive effect of mu receptor agonists (Rotha et al., 1998). Also, long-term use of 
opioids such as morphine or oxycodone results in the development of tolerance to the 
analgesic effect, and causes drug abuse and dependence, as well as significant side effects 
such as respiratory depression, constipation, and cognitive impairment.  
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Anticonvulsant drugs such as GABA-pentin (Neurotin ®) and pregablin (Lyrica ®) 
are often used to treat neuropathic pain, but have limited efficacies. An antidepressant,  
Duloxetine (Cymbalta®) has been recently approved for the treatment of diabetic 
neuropathy, but this drug is also associated with significant side-effects (Patacchioli, 
2004). 
 
The limitations of currently available treatments for nociceptive and neuropathic 
pain clearly indicate the need for new approaches. One approach to address this problem 
is to consider combining analgesic drugs from other classes with opioids. The theory 
behind this is to lower the dose to avoid side effects, in addition to covering a broad 
spectrum of pain, i.e., to treat both nociceptive and neuropathic pain. The two combined 
drugs should produce a synergistic effect rather than just an additive effect. In this regard, 
one group of drugs that appears particularly promising for combination with the opioids 
is the cannabinoids (Patacchioli, 2004).  
 
1.5.3 Pharmacokinetics and Pharmacodynamics of Cannabinoids 
 
Cannabinoids are useful for the treatment of pain, spasticity, glaucoma and other 
disorders. But they have numerous side-effects too, such as increase in heart rate, 
lowering of blood pressure, appetite stimulation, dry mouth and dizziness (Patacchioli, 
2004). The Cannabis plant contains several cannabinoids, one of which is ∆ 9-
tetrahydrocannabinol (∆9-THC) which possesses most of the characteristic 
pharmacological effects (Patacchioli, 2004). Fig. 1.15 shows the chemical structure of ∆ 9-
THC. It is yellow resinous oil, sticky at room temperature, which hardens upon 
refrigeration; it is without smell and has bitter taste. The molecular weight of ∆ 9-THC is 
314.45, and the molecular formula is C21H30O2. ∆9-THC is highly insoluble in water but 
soluble in ethanol/methanol. 
Oral administration of ∆ 9-THC leads to erratic uptake of the drug as a result of 
degradation by stomach acids and extensive liver first-pass metabolism (Howelett and 
Barth, 2002). The measured bioavailability of ∆ 9-THC after oral administration (Marinol) 
is only 10-20%. Since it is highly lipophilic, high concentrations of the drug are found in 
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highly vascularized tissues shortly after oral administration of the drug, which is reflected 
in a high volume of distribution of about 10 L/kg. ∆ 9-THC also binds strongly to plasma 
proteins, only about 3% of the drug being in the unbound form. The major 
biotransformation product of ∆ 9-THC is the monohydroxy metabolite, 11-hydroxy-∆9-
THC (THC-OH), which also binds to plasma proteins very strongly (Howelett and Barth, 
2002). 
 
More than 100 metabolites of ∆ 9-THC have already been identified. Due to its 
high lipid solubility, ∆ 9-THC is a good substrate for cytochrome P450 mixed-function 
oxidases (Rotha et al., 1998; Patacchioli, 2004; Howelett and Barth, 2002). ∆ 9-THC is 
hydroxylated at both C11 and C8, and at all the positions of the alkyl side-chain. Fig. 
1.19 shows the possible oxidation sites for ∆ 9-THC. 
 
Fig. 1.19 Possible metabolic oxidation sites of ∆9-THC 
 
∆9-THC, like any other very lipophilic drug, has long terminal half-life, due to its 
deposition in tissues. The complete elimination time is very difficult to estimate, due to 
the slow equilibration of plasma and tissue concentrations. The literature half-life value 
varies between 1-4 days, while complete elimination may well take up to 5 weeks (Rotha 
et al., 1998; Patacchioli, 2004; Howelett and Barth, 2002). ∆ 9-THC is excreted both in 
urine and feces as metabolites. Most urinary metabolites are acids. The main metabolite 
found in urine is the THC-COOH glucuronide, which, when normalized to the creatinine 
concentration, can be used for the detection and monitoring of Cannabis drug abuse. ∆ 9-
THC also undergoes extensive enterohepatic recycling, which also contributes to its slow 
elimination (Rotha et al., 1998; Patacchioli, 2004; Howelett and Barth, 2002). 
 
33 
 
Cannabinoid receptors have been identified in both the brain and the immune 
system. They are denoted by the abbreviation CB, and numbered in the order of their 
discovery by a subscript (Howelett and Barth, 2002). Two distinct cannabinoid receptors, 
CB1 and CB2 have been cloned. The CB1 receptor is a GPCR receptor located in the 
central nervous system. It is expressed strongly in the basal ganglia, cerebellum, 
hippocampus and in the dorsal primary afferent spinal cord region (Howelett and Barth, 
2002; Williams et al., 2006). The localization of CB1 receptors clearly indicates their 
effectiveness in memory impairment, analgesia and addiction. The CB2 receptor exhibits 
48% homology with the CB1 receptor. CB2 receptor mRNA is found mainly in immune 
tissues, and is notably absent from normal nervous tissue (Howelett and Barth, 2002). ∆ 9-
THC and other cannabinoid receptor agonists show therapeutic effects as analgesics, 
lessen feelings of nausea and vomiting in cancer chemotherapy, cause appetite 
stimulation in wasting syndromes, and provide relief from muscle spasms. The main side-
effects are alterations in cognition and memory, dysphoria/euphoria, and sedation. 
Synthetic agonists that bind to cannabinoid receptors are usually ∆ 9-THC analogs and 
aminoalkylindole compounds. Most notable endogenous cannabinoid ligands are 
anandamide (arachidonoylethanolamide), 2-arachidonoylglycerol, and 2-
arachidonoylglyceryl ether. Anandamide and 2-arachidonoylglycerol function as 
neurotransmitters or neuromodulators, and act as retrograde synaptic messengers 
(Howelett and Barth, 2002). They are synthesized by neurons on demand, and undergo 
depolarization-induced release from neurons and after their release they are rapidly 
removed from the extracellular space by a membrane transport system process. This 
process still remains to be fully characterized. Once within the cell, anandamide is 
hydrolyzed to arachidonic acid and ethanolamine by fatty acid amide hydrolase (FAAH).  
 
When agonists bind to cannabinoid receptors, they activate a number of signal 
transduction pathways via the Gi/o family of G proteins. Free Giα proteins regulate adenyl 
cyclase, leading to an inhibition of cyclic AMP production. This inhibits phosphorylation 
by protein kinase A, leading to modulation of signaling pathways, especially ion channels 
(Williams et al., 2006).  An interaction between CB1 receptors and phospholipase C was 
demonstrated in cultured cerebellar granule neurons, in which cannabinoid agonists 
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augmented the Ca2+ signal in response to NMDA receptor stimulation of K+ 
depolarization (Howelett and Barth, 2002). 
 
A body of evidence suggests the existence of independent but interacting 
mechanisms of modulation of antinociception by cannabinoid and opioid systems 
(Hohman et al., 1999). It has been shown previously that ∆ 9-THC and morphine show 
synergistic effects in the production of antinociception (Williams et al., 2006). There is a 
similar distribution of CB1 cannabinoid and mu opioid receptors in the dorsal horn of the 
spinal cord and in central nervous system (Bidaut-Russell and Howlett, 1988). Opioids 
and cannabinoids also produce similar effects on calcium levels and cyclic AMP 
accumulation through G protein receptors (Reche et al., 1996). Importantly, cannabinoids 
have been shown to produce analgesia through interaction with kappa opioid receptors in 
the spinal cord by releasing endogenous opioids (Hohman et al., 1999). 
 
A synergism between morphine and ∆9-THC has also been observed in the spinal 
cord of mice. Inactive doses of both morphine and ∆ 9-THC showed a greater than 
additive effect when given by i.v. administration (Bidaut-Russell and Howlett, 1988; 
Reche et al., 1996). A mixture of these two drugs produced an analgesic effect through 
mu opioid receptor- as well as CB1 cannabinoid receptor-mediated pathways. 
 
Since, a codrug strategy has been reported useful for improving the 
physicochemical and pharmacokinetic properties of the parent drugs; the next chapter 
reports the synthesis of opioid and cannabinoid codrugs. Later on, their pharmacological 
and pharmacokinetic evaluation has been carried to compare their efficacies with parent 
drugs and physical mixtures of the parent drugs. 
 
 
 
 
 
Copyright © Harpreet Dhooper 2010 
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Chapter 2 
Synthesis of Codrugs and Parent drugs 
 
2.1 Synthesis of ∆9-Tetrahydrocannabinol (∆9-THC)  
 
∆9-THC synthesis was carried out in two steps. In the first step, (+)-limonene 
oxide (mixture of cis and trans isomers) was added to a stirred suspension of sodium 
borohydride and diphenyldiselenide in dry ethanol under a nitrogen atmosphere. The 
mixture was refluxed for 2 hrs and then after cooling, hydrogen peroxide was added 
drop-wise. After work up, the solvent was evaporated under reduced pressure and column 
chromatography was carried out using hexanes:diethyl ether gradient to obtain pure 
(1S,4R)-p-mentha-2,8-dien-1-ol (Rickards and Watson, 1980). The selenoxide 
intermediate was characterized by X-ray diffraction (Fig. 2.1) and (1S,4R)-p-mentha-2,8-
dien-1-ol was characterized by GC-MS (Fig 2.2) and NMR spectroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1 Single crystal X-ray structure of the selenoxide intermediate in the synthesis of 
∆9-THC  
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In the second step, BF3.Et2O was added drop-wise to a stirred suspension of 
(1S,4R)-p-mentha-2,8-dien-1-ol, olivetol and anhydrous magnesium sulfate in methylene 
chloride at 0 °C under a nitrogen atmosphere. The mixture was stirred for 2 hrs at 0 °C, 
and then anhydrous sodium bicarbonate was added.  After workup, column 
chromatography over silica was carried out using a hexanes:diethyl ether gradient to 
obtain pure ∆9-THC (Scheme 2.1) (Razdan et al., 1974). The final product was 
characterized by GC-MS (Fig. 2.2) and NMR spectroscopy. 
 
Scheme 2.1: Synthesis of ∆ 9-THC 
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2.2 Synthesis of (-)-Cannabidiol (CBD)   
 
A GC-MS of (+)-limonene oxide (mixture of cis and trans isomers) was recorded 
before starting this synthesis, to check the purity of the compound, and also to help in 
monitoring the progress of the initial reaction. In Fig. 2.3, a GC of (+)-limonene oxide is 
illustrated which shows the peaks attributed to cis and trans limonene oxides having 90 
% matches in the Wiley database.  
 
In the first step of the synthesis of (-)-cannabidiol, morpholine was added to a 
stirred solution of LiCl and limonene oxide in ethanol and the reaction mixture was 
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heated at 70 °C (Scheme 2.2). The progress of the reaction was monitored by GC-MS. 
Fig. 2.4, shows the GC-MS of the reaction after 6 hrs, and after 24 hrs. The GC-MS after 
24 hrs showed complete disappearance of the trans-(+)-limonene oxide peak. Longer 
reaction times allowed the cis-(+)-limonene oxide to react with morpholine. Thus, the 
reaction was stopped after 24 hrs. The solvent was evaporated under reduced pressure 
after work up; the product, 4-isopropenyl-1-methyl-2-morpholin-4-yl-cyclohexanol, was 
obtained as a yellow oil. The GC-MS of this product is shown in Fig. 2.5 (Gu et al., 
2004). 
                 
   
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 2.2 The GC-MS of ∆9-THC 
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Fig. 2.3 The GC-MS of (+)-limonene oxide 
 
Scheme 2.2: Synthesis of (1S,4R)-p-mentha-2,8-dien-1-ol 
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In the second step of synthesis of (-)-cannabidiol, hydrogen peroxide was added 
to the yellow oil resulting from the first step of the synthesis, and the resulting solution 
was heated for 4 hrs.10 % Pd on C was then added to decompose the remaining hydrogen 
peroxide, and the reaction mixture was filtered through a pad of celite. The filtrate was 
evaporated under reduced pressure to afford yellow oil. Silica gel column 
chromatography was carried out to purify the compound using a hexanes:ethyl acetate 
gradient followed by elution with methanol, to afford a pure fraction of 4-isopropenyl-1-
methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol.  
 
4-Isopropenyl-1-methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol was dissolved in 
toluene and silica was added. The resulting mixture was heated to reflux with stirring. 
The literature procedure recommends the use of a Dean and Stark apparatus, but product 
formation was observed when under these conditions. As an alternative, the solution was 
refluxed overnight and the silica was then removed by filtration. The filtrate was 
evaporated under reduced pressure to afford a brown oil, which consisted of the product, 
(1S,4R)-p-mentha-2,8-dien-1-ol and a small amount of (1R,4R)-p-mentha-2,8-dien-1-ol 
as a byproduct. The crude (1S,4R)-p-mentha-2,8-dien-1-ol was purified by silica gel 
column chromatography using a hexanes:diethyl ether gradient and the final product was 
characterized by GC-MS (89% match with Wiley database) (Fig. 2.6) and NMR 
spectroscopy (Chen et al., 2007).  
 
In the last step of the synthesis, a mixture of olivetol, zinc chloride, water and 
dichloromethane was refluxed and (1S,4R)-p-mentha-2,8-dien-1-ol was added drop-wise 
(Scheme 2.3). It is advisable to add (1S,4R)-p-mentha-2,8-dien-1-ol very slowly to avoid 
the formation of side-products. The progress of the reaction was monitored by GC-MS. 
After the completion of the reaction, the solvent was evaporated, and the crude mixture 
was characterized by GC-MS, which indicated that it contained (-)-cannabidiol, 
abnormal-cannabidiol (abn-CBD), olivetol and traces of ∆ 9-THC (Fig. 2.7). Column 
chromatography over silica gel was carried out on the crude product using a 
hexanes:diethyl ether gradient. The fractions obtained were characterized by GC-MS and 
NMR spectroscopy (Choi et al., 2004). A pure fraction of (-)-cannabidiol was obtained 
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and was characterized by GC-MS (Fig. 2.8). An NMR spectrum of the synthesized (-)-
cannabidiol compared favorably with that of (-)-cannabidiol reported by Gutman et al., 
2006. 
 
 
Fig. 2.4 GC-MS of reaction mixture for the synthesis of 4-isopropenyl-1-methyl-2-(4-
oxy-morpholin-4-yl)-cyclohexanol after 6 hrs and 24 hrs 
GC after 6 hrs 
GC after 24 hrs 
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Fig. 2.5 The GC-MS of 4-isopropenyl-1-methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol 
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Fig. 2.6 The GC-MS of (1S,4R)-p-mentha-2,8-dien-1-ol 
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Scheme 2.3: Synthesis of (-)-cannabidiol and abnormal-cannabidiol 
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    Fig. 2.7 The GC-MS of the crude mixture from (-)-cannabidiol synthesis 
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Fig. 2.8 The GC of synthesized (-)-cannabidiol 
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Fig. 2.9(a) The MS of synthesised (-)-cannabidiol 
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    Fig. 2.9 (b) The MS of a reference standard of (-)-cannabidiol 
 
Fig. 2.10 The GC of abn-cannabidiol 
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Fig. 2.11 (a) MS of abn-cannabidiol and (b) MS of a reference standard of (-)-cannabidiol 
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2.3 Codeine-∆9-Tetrahydrocannabinol (Cod-THC) Codrug Synthesis 
 
Before starting the synthetic work with expensive controlled substances such as 
codeine and ∆9-THC, coupling reactions were initially carried out with model compounds 
or chemical-mimics of the drug molecules to optimize the desired chemistry. 3-
Ethylphenol was chosen as the model compound for both codeine and ∆9-THC. 
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       Fig. 2.12 Structures of morphine, codeine (1), 3-ethylphenol (2) and Δ9-THC (3) 
 
Since the essential conjugation chemistry in the synthesis of the Cod-THC codrug 
is the formation of a carbonate linkage, reactions were initiated to generate carbonate 
linkages with phenols. Initially, a symmetrical carbonate ester of 3-ethylphenol was 
formed utilizing triphosgene and pyridine (Scheme 2.4) (Burk and Roof, 1993). 
 
Scheme 2.4: Synthesis of a symmetrical carbonate of 3-ethylphenol 
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Unfortunately, 3-ethylphenol obtained from Aldrich was only 80% pure, the 
major of the impurity being 4-ethylphenol, thus a pure sample of desired product was 
unattainable. Due to this problem, use of 3-ethylphenol in the model reactions was 
replaced with 4-ethylphenol, since 4-ethylphenol from Aldrich was 98% pure. The same 
conjugation reaction was carried out with 4-ethylphenol and afforded the desired 
symmetrical carbonate. 
 
The next aim was to form a carbonate linked product using two different phenols. 
For this purpose 4-ethylphenol and 5,6,7,8-tetrahydro-2-naphthol were used as model 
compounds. The reaction between these two phenols in the presence of triphosgene and 
triethyl amine produced 3 different carbonates, two symmetrical carbonates along with 
the desired unsymmetrical carbonate. GC-MS analysis showed almost equal quantities of 
all three carbonates in reaction mixture (Scheme 2.5). 
 
Scheme 2.5: Conjugation of two different phenolic compounds utilizing triphosgene 
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In the above reaction, as there was no selectivity observed for the formation of the 
desired unsymmetrical carbonate over the two symmetrical carbonates, it was anticipated 
that purification of the unsymmetrical carbonate would present a difficult challenge. 
Thus, a different synthetic approach was devised utilizing the intermediacy of a 
chloroformate analogue. Initially, one of the phenolic starting materials was converted to 
a chloroformate derivative, and then the other phenolic starting material was reacted with 
the chloroformate derivative to afford the unsymmetrical carbonate product (Scheme 2.6) 
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(Martin et al., 2006). Utilizing triethylamine as a base in the second step of the coupling 
reaction afforded better yield and less amount of side product formation (Scheme 2.7). 
 
  
Scheme 2.6: Synthesis of an unsymmetrical carbonate of 4-ethylphenol and 5,6,7,8-
tetrahydro-2-naphthol 
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Scheme 2.7: Synthesis of an unsymmetrical carbonate of 4-ethylphenol and 5,6,7,8-
tetrahydro-2-naphthol utilizing triethylamine 
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Since codeine contains an OH group and a basic tertiary N-atom, 3-quinuclidinol 
was chosen as a more appropriate chemical-mimic for codeine. 4-Ethylphenol was 
retained as the model molecule for ∆ 9-THC. In the next series of reactions the 
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chloroformate of 4-ethylphenol was initially formed and then reacted with 3-
quinuclidinol to form the carbonate of 4-ethylphenol and 3-quinuclidinol (Scheme 2.8). 
 
 
Scheme 2.8: Synthesis of an unsymmetrical carbonate of 4-ethylphenol and 3-
quinuclidinol 
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There were some problems associated with the formation of the chloroformate 
intermediate. The reaction was never clean, and there was always formation of a 
symmetrical carbonate as a side-product together with the formation of the desired 
chloroformate. Due to this problem a new synthetic method was sought for the exclusive 
synthesis of the unsymmetrical carbonate. 
 
p-nitrophenylchloroformate analogues have been described in the literature for the 
formation of unsymmetrical carbonates and carbamates (Anderson and McGregor, 1957). 
Initially, an alcohol (A) is reacted with p-nitrophenylchloroformate to form the carbonate 
conjugate of A and p-nitrophenol. This intermediate is then reacted with another 
alcohol/phenol (B) to form the carbonate conjugate of A and B. In the second step, the 
good leaving group property of p-nitrophenol is advantageous in selective formation of 
the desired unsymmetrical carbonate (Scheme 2.9). 
 
3-Quinuclidinol was allowed to react with p-nitrophenylchloroformate in the 
presence of a base to form the carbonate of 3-quinuclidinol and p-nitrophenol (Scheme 
2.9a). 
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Scheme 2.9a: Synthesis of carbonate of 3-quinuclidinol and p-nitrophenol 
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In the next step, the carbonate of 3-quinuclidinol and p-nitrophenol was allowed 
to react with codeine to form the desired unsymmetrical 3-quinuclidinol-codeine 
carbonate (Scheme 2.9b). 
 
 
 
 
Scheme 2.9b: Synthesis of unsymmetrical 3-quinuclidinol-codeine carbonate 
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The carbonate ester of 3-quinuclidinol and codeine was also successfully 
synthesized via the alternative route by first forming the p-nitrophenol carbonate of 
codeine and then reacting this intermediate with 3-quinuclidinol (Scheme 2.10). 
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Scheme 2.10: Synthesis of unsymmetrical carbonate codeine and 3-quinuclidinol via the 
intermediacy of codeine-p-nitrophenol carbonate 
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The latter approach was problematic, in that formation of the symmetrical 
carbonate of codeine was formed along with the desired unsymmetrical carbonate.  
 
 
Scheme 2.11: Formation of carbonate of codeine and p-nitrophenol using triethylamine 
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This problem was solved by utilizing a different base (DMAP), and by varying 
the reaction time and temperature (Scheme 2.12). The purity of the unsymmetrical 
carbonate was checked by NMR spectroscopy and by analytical HPLC. Fig. 2.14 shows 
the chromatograms of p-nitrophenol, codeine, ∆ 9-THC and codeine-p-nitrophenol 
carbonate (Cod-PNP). A UV wavelength of 220 nm was used for the detection. An 
Apollo C18 reverse phase column was used as the stationary phase, and 80:20 
Acetonitrile:NH4OAc buffer (pH 4.5) was used as the mobile phase with a 1 ml/min flow 
rate. 
 
 
Scheme 2.12: Formation of carbonate of codeine and p-nitrophenol using DMAP 
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The next step was to form the actual codrug by reacting the p-nitrophenol 
carbonate of codeine with ∆ 9-THC. This reaction was carried out in the presence of 
DMAP as a base, and the reaction mixture was refluxed overnight. Formation of the 
product was confirmed by recording the MALDI spectrum of the product from the 
reaction mixture (Scheme 2.13). 
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Fig. 2.13 MALDI spectrum of codeine-p-nitrophenol carbonate 
 
 
 
Fig. 2.14 HPLC chromatograms of different analytes (p-nitrophenol, codeine, ∆ 9-THC, 
codeine-p-nitrophenol carbonate) 
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Scheme 2.13: Synthesis of carbonate of codeine and ∆ 9-THC 
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The above reaction was carried out several times by varying the base (DMAP or 
triethylamine) and varying the reaction temperatures and solvents, but the reaction never 
went to completion. Although the MADLI spectrum showed evidence for the formation 
of the desired codrug, TLC monitoring of the reaction mixture showed only a faint spot 
of the product and intense spots of the starting materials. Since conventional chemical 
reactions could not solve the problem of incomplete conversion to product, microwave 
reactions were explored (de la Hoz et al., 2005). In an initial attempt, the carbonate of 
codeine and p-nitrophenol was reacted with 4-ethylphenol in a microwave oven in 
presence of a base (TEA) and in absence of any solvent (Scheme 2.14a). The reaction 
mixture was irradiated for 30 seconds followed by TLC monitoring. No further progress 
of the reaction was noticed after 2 minutes of total microwave irradiation time. 
 
Scheme 2.14 (a): Synthesis of unsymmetrical carbonate of codeine and 4-ethylphenol 
utilizing microwave irradiation 
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In another attempt, the reaction between the carbonate of codeine and p-
nitrophenol and 5,6,7,8-tetrahydro-2-naphthol was performed under microwave 
conditions. The reaction mixture was irradiated for 30 seconds followed by TLC 
monitoring. No further progress of the reaction was noticed after 2 mins of total 
microwave irradiation time (Scheme 2.14b). 
 
 
Scheme 2.14(b): Synthesis of unsymmetrical carbonate of codeine and 5,6,7,8-
tetrahydro-2-naphthol utilizing microwave irradiation  
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Both of the model microwave reactions showed positive results and showed the 
evidence of formation of the desired carbonates (around 20% conversion to product) in 
both the MALDI and NMR spectra. 
 
Next, the microwave-mediated reaction between the carbonate of codeine and p-
nitrophenol and ∆ 9-THC was performed. The reaction mixture was heated in the 
microwave oven for 30 seconds in the presence of TEA and then analyzed by HPLC. The 
results indicated that the desired product had been formed but the reaction was still 
incomplete, and in addition to the starting materials, the symmetrical carbonate was also 
present in the reaction mixture (Scheme 2.14c). 
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Scheme 2.14(c): Synthesis of unsymmetrical carbonate of codeine and ∆ 9-THC utilizing 
microwave irradiation  
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Since microwave-mediated reactions were not a complete success, a conventional 
approach was again explored, focusing first on the reaction of the para-nitrophenol 
carbonate of codeine with ∆9-THC. In this reaction, ∆9-THC was treated first with NaH at 
low temperature, followed by drop-wise addition of the p-nitrophenol carbonate of 
codeine (Scheme 2.15). The product yield obtained was better than the previous attempts 
(43%). MALDI analysis and NMR spectral analysis showed no sign of formation of the 
symmetrical carbonate of codeine. 
 
Silica gel column chromatography of the reaction product using a 
dichloromethane-methanol gradient was performed to purify the compound. MALDI, 
HRMS and NMR spectral analysis confirmed structure of the pure Cod-THC codrug 
(Fig. 2.15, 2.16).  
 
The analysis of the Cod-THC codrug by HPLC-UV assay was carried out. 
Detection was at 220 nm and an Apollo ® C18 (5 µm, 3.9 x 150 mm) column, equipped 
with a guard column (Nova-Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary 
phase; methanol/6mM phosphate buffer containing 0.025% heptafluorobutyric acid 
(HFBA), pH adjusted to 6.9 with triethylamine, was used as the mobile phase. A gradient 
program with a flow rate of 1mL/min was used for the elution of the Cod-THC codrug 
molecule. Fig. 2.17 shows the chromatogram of the Cod-THC codrug.  
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Scheme 2.15: Synthesis of unsymmetrical carbonate of codeine and ∆ 9-THC utilizing a 
stronger base (NaH) 
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Fig. 2.15 The MALDI analysis of the Cod-THC codrug 
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Fig. 2.16 High resolution electron impact ionization mass spectrum of the Cod-THC 
codrug 
 
 
 
Fig. 2.17 HPLC chromatogram of chromatogram the Cod-THC codrug 
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2.4 Synthesis of the Codeine-(-)-Cannabidiol codrug (Cod-CBD)  
 
The Cod-CBD codrug was synthesized in a similar manner to the successful 
synthesis of the Cod-THC codrug. First, the intermediate para-nitrophenol carbonate of 
codeine was prepared. Then, (-)-cannabidiol was treated with NaH and then the para-
nitrophenol carbonate of codeine was added drop-wise to the reaction mixture. Scheme 
2.16 shows the synthesis of the Cod-CBD codrug. Silica gel column chromatography was 
again carried out in order to purify the desired codrug using a dichloromethane-methanol 
gradient. The compound was characterized by NMR spectroscopy, HRMS (Fig. 2.18) and 
LC-MS analysis (Fig. 2.19). 
 
 
Scheme 2.16: Synthesis of carbonate of codeine and (-)-cannabidiol  
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2.5 Synthesis of the Codeine-abn-Cannabidiol codrug (Cod-abnCBD)  
 
The Cod-abnCBD codrug was synthesized in a similar manner to the Cod-THC 
and Cod-CBD codrugs. Scheme 2.17 depicts the synthesis of the Cod-abnCBD codrug. 
Silica gel column chromatography was performed again to obtain a pure sample of the 
desired codrug using a dichloromethane-methanol gradient. The compound was 
characterized by NMR and mass spectral analysis (Fig. 2.20). 
 
Scheme 2.17: Synthesis of carbonate of codeine and abnormal-cannabidiol 
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Fig. 2.18 High-resolution electron impact ionization mass spectrum of the Cod-CBD  
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Fig. 2.19 LC-MS analysis of the Cod-CBD codrug 
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Fig. 2.20 High resolution electron impact ionization mass spectrum of the Cod-abnCBD 
codrug 
 
2.6 Synthesis of the 3-O-Acetylmorphine-∆9-tetrahydrocannabinol codrug (AcMor-
THC)  
 
AcMor-THC codrug synthesis was carried out in three steps. In the first step, 3-O-
acetylmorphine was synthesized by regioselective 3-O-acetylation of morphine free base 
using acetic anhydride and sodium bicarbonate. 3-O-Acetylmorphine was then allowed to 
react with para-nitrophenylchloroformate to afford the 6-O-carbonate of 3-O-
acetylmorphine and para-nitrophenol. Finally, the intermediate carbonate was allowed to 
react with phenoxide ion of ∆ 9-THC to afford the desired product, 3-O-acetylmorphine-
∆9-tetrahydrocannabinol carbonate (AcMor-THC). 3-O-Acetylmorphine, 3-O-
acetylmorphine-para-nitrophenol carbonate intermediates and the final AcMor-THC 
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codrug product were all characterized by GC-MS, LC-MS, ESI-MS, and NMR and 
HRMS analysis (Scheme 2.18) (Crooks et al., 2002).  
 
 
 
 
Fig. 2.21 GC-MS spectrum of 3-O-acetylmorphine 
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Scheme 2.18a: Synthesis of 3-O-acetylmorphine 
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Scheme 2.18 b:Synthesis of 6-O-carbonate of 3-O-acetylmorphine and para-nitrophenol  
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Scheme 2.18c: Synthesis of 3-O-acetylmorphine-∆9-tetrahydrocannabinol carbonate 
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Fig. 2.22 ESI-MS of 3-O-acetylmorphine-para-nitrophenol carbonate (AcMor-PNP) 
 
Fig. 2.23 High resolution electron impact ionization mass spectrum of the 3-O-
acetylmorphine-∆9-tetrahydrocannabinol codrug 
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Fig. 2.24 ESI-MS of 3-O-acetylmorphine-∆9-tetrahydrocannabinol codrug 
 
Experimental section 
 
General Procedures. All experimental procedures were carried out under 
nitrogen and in oven-dried glassware unless otherwise mentioned. Solvents and reagents 
were obtained from commercial vendors. All solvents were removed by evaporation 
using a rotary evaporator unless indicated otherwise. 
 
1H and 13C NMR spectra were recorded on Varian 300MHz and 500MHz 
spectrometers. HPLC analyses were carried on an Agilent 1100 series Quatpump, 
equipped with a photodiode array detector and a computer integrating apparatus. GC-MS 
analyses were carried out on an Agilent 6890 GC instrument attached to a 593 mass- 
selective detector. Microwave reactions were carried out on a Biotage 355422-AD 
microwave synthesizer. High-resolution mass spectrometry was performed by the 
University of Kentucky Mass Spectrometry facility. X-ray crystallography was 
performed by the University of Kentucky Crystallographic facility. 
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Synthesis of ∆9-Tetrahydrocannabinol. 
 
OH  
 
(1S,4R)-p-Mentha-2,8-dien-1-ol. Sodium borohydride (0.266 g, 7.02 mmol) was 
added portion-wise to a stirred suspension of diphenyldiselenide (1.0 g, 3.2 mmol) in dry 
ethanol (16 mL) under nitrogen atmosphere. A mixture of cis- and trans- limonene oxide 
(0.870 g, 5.72 mmol) was added, and the resultant mixture was refluxed for 2 h. After 
cooling in an ice-bath, THF (15 mL) was added followed by drop-wise addition of 35% 
v/v hydrogen peroxide (1.7 mL). The solution was allowed to warm to ambient 
temperature and stirred for 5 h, and then diluted with water (40 mL). The organic layer 
was separated. The aqueous layer was extracted with methylene chloride, and the 
combined organic liquors were washed with 10% aqueous sodium carbonate, water, and 
saturated brine, dried over anhydrous sodium sulfate and concentrated on a rotary 
evaporator. The residue containing the selenoxide intermediate was utilized in the next 
step without any further purification. The selenoxide intermediate was heated for 8 h in 
refluxing chloroform (13.5 mL) under a nitrogen atmosphere. After cooling, the solvent 
was evaporated and the residue was extracted with diethyl ether. The solvent was 
evaporated and the crude product was purified through silica gel column chromatography 
to afford pure (1S,4R)-p-mentha-2,8-dien-1-ol (0.213 g, 25%). The elution was carried 
out with hexanes and increasing portions of diethyl ether up to 5:1 of hexanes:diethyl 
ether. 1H NMR (300 MHz, CDCl3): δ 5.63 (2H, m), 4.70 (2H, m), 2.59 (1H, m), 1.41-
1.90 (7H, m), 1.25 (3H, s) ppm; 13C NMR (300 MHz, CDCl3): δ 148.1, 133.9, 132.1, 
110.6, 67.4, 43.4, 36.7, 29.4, 24.9, 20.8 ppm; GC-MS M+ 152 m/z. 
 
OH
O  
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∆9-Tetrahydrocannabinol. Boron trifluoride etherate (0.09 mL) was added drop-
wise to an ice-cold stirred suspension of (1S,4R)-p-mentha-2,8-dien-1-ol (0.213 g, 1.4 
mmol), olivetol (0.263 g, 1.38 mmol) and anhydrous magnesium sulfate (0.185 g) in 
methylene chloride (9.25 mL) under nitrogen. The mixture was stirred for 2 h at 0 °C, 
and then anhydrous sodium bicarbonate (0.462 g) was added. Stirring was continued until 
the color faded to a light brown, and the reaction mixture was then filtered and 
evaporated to provide a brown gum. The crude product of ∆9-THC was purified using 
silica gel column chromatography. Elution was carried out with hexanes with increasing 
portion of diethyl ether in hexanes (up to 30:1 hexanes:diethyl ether) to afford a pure 
fraction of ∆9-THC (100 mg, 22%). 1H NMR (300 MHz, CDCl3): δ 6.29 (1H, br s), 6.25 
(1H, d, J=1.2 Hz), 6.12 (1H, d, J=1.2 Hz), 4.78 (1H, s), 3.18 (1H, br d), 3.42 (2H, t, J=7.2 
Hz), 1.20-2.21 (17H, m), 1.07 (3H, s), 0.86 (3H, t, J=7.2 Hz) ppm; 13C NMR (300 MHz, 
CDCl3): δ 154.8, 154.2, 142.9, 134.5, 123.8, 110.2, 109.2, 107.7, 77.4, 46.0, 35.8, 33.8, 
31.8, 31.4, 31.0, 27.9, 25.3, 23.7, 22.9, 19.6, 14.4 ppm; GC-MS M+ 314 m/z. 
Synthesis of (-)-Cannabidiol and abn-Cannabidiol. 
 
OH
N
O
 
 
4-Isopropenyl-1-methyl-2-morpholin-4-yl-cyclohexanol. (+)-Limonene oxide 
(a mixture of cis and trans isomers) (5.0 g, 0.033 moles) was dissolved in ethanol (16 
mL) and LiCl (2.247 g, 0.053 moles) was added while stirring the solution. Morpholine 
(4.295 g, 0.049 moles) was added drop-wise and the reaction mixture was heated at 70 °C 
for 24 hours. The progress of the reaction was monitored by GC-MS. After almost all of 
the trans-(+)-limonene oxide had been consumed solvent was evaporated under reduced 
pressure and the residue was taken up into methylene chloride solvent (100 mL). The 
organic solution was washed with water (80 mL) and then extracted into 2M hydrochloric 
acid (2 x 60 mL) and the aqueous acidic solution was washed with methylene chloride (2 
x 50 mL). The aqueous solution was basified to pH 10 by addition of 2M sodium 
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hydroxide. The basic aqueous solution was extracted with diethyl ether (4 x 60 mL) and 
the organic liquors washed with water (3 x 50 mL). The diethyl ether solution was dried 
over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. 
The desired product was obtained as yellow oil (3.38g, 43%). 1H NMR (300 MHz, 
CDCl3): δ 4.94 (2H, m), 4.85 (1H, m), 3.70 (4H, m), 2.72 (2H, m), 2.52 (4H, m), 2.10 
(1H, m), 2.05 (1H, m), 1.98 (1H, m), 1.74 (3H, s), 1.60 (4H, m), 1.21 (3H, s) ppm; 13C 
NMR (300 MHz, CDCl3): δ 145.6, 111.3, 73.0, 67.9, 67.8, 52.3, 45.8, 39.3, 36.0, 25.3, 
24.9, 22.8, 22.7 ppm; GC-MS M+ 239 m/z. 
 
 
 
OH
N
O
O
 
 
4-Isopropenyl-1-methyl-2-(4-oxy-morpholin-4-yl)-cyclohexanol. 4-
Isopropenyl-1-methyl-2-morpholin-4-yl-cyclohexanol (3.596 g, 0.015 moles) was 
dissolved in ethanol (21 mL) and 35 % v/v hydrogen peroxide (7.52 mL) was added 
drop-wise. The solution was heated at 50 °C for 4 h. 10 % Pd on C (20.32 mg) was added 
at room temperature, the mixture was stirred for 2 h, and the solvent was evaporated 
under reduced pressure to afford a yellow oil. This oil was submitted to silica gel column 
chromatography using a hexanes:ethyl acetate gradient with the final elution with 
methanol to afford the desired product (3.38 g, 88%). 1H NMR (300 MHz, CDCl3): δ 
4.99 (1H, m), 4.80 (1H, m), 4.48 (2H, m), 3.69 (3H, m), 3.38 (2H, m), 3.20 (1H, m), 2.81 
(1H, m), 2.60 (1H, m), 2.20 (1H, m), 1.46-2.00 (12H, m) ppm; 13C NMR (300 MHz, 
CDCl3): δ 143.9, 112.1, 80.1, 73.7, 65.3, 61.5, 61.3, 59.4, 39.8, 39.3, 28.7, 24.7, 23.6, 
22.6 ppm. 
 
OH  
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(1S,4R)-p-Mentha-2,8-dien-1-ol. 4-Isopropenyl-1-methyl-2-(4-oxy-morpholin-4-
yl)-cyclohexanol (5.41 g, 0.021 moles) was dissolved in toluene (94 mL) and silica (1.3 
g) was added. The reaction mixture was heated to reflux with stirring overnight. The 
silica was then removed by filtration. The filtrate was evaporated under reduced pressure 
to afford a brown oil. This oil was dissolved in methylene chloride (50 mL) and washed 
with 2M hydrochloric acid (2 x 30 mL). The methylene chloride solution was washed 
with water (2 x 25 mL) and finally dried over anhydrous sodium sulfate. The solvent was 
evaporated under reduced pressure to afford the crude product (1S,4R)-p-mentha-2,8-
dien-1-ol. The crude product was chromatographed on silica using a hexanes-diethyl 
ether gradient to afford pure (1S,4R)-p-mentha-2,8-dien-1-ol (0.77 g, 24%). 1H NMR 
(300 MHz, CDCl3): δ 5.63 (2H, m), 4.70 (2H, m), 2.59 (1H, m), 1.41-1.90 (7H, m), 1.25 
(3H, s) ppm; 13C NMR (300 MHz, CDCl3): δ 148.1, 133.9, 132.1, 110.6, 67.4, 43.4, 36.7, 
29.4, 24.9, 20.8 ppm; GC-MS M+ 152 m/z. 
 
OH
HO OHHO
CBD abn-CBD  
 
 
(-)-Cannabidiol and abn-Cannabidiol. A mixture of olivetol (1.18 g, 6.55 
mmol), zinc chloride (1.35 g, 0.0429 mmol) water (0.115 mL, 0.029 mmoles) and 
methylene chloride (11.4 mL) was refluxed for 1 h. (1S,4R)-p-Mentha-2,8-dien-1-ol (1.0 
g, 6.57 mmol), dissolved in methylene chloride was then added drop-wise and the 
mixture refluxed for an additional 1 h. the progress of the reaction was monitored by GC-
MS. After complete consumption of (1S,4R)-p-mentha-2,8-dien-1-ol, the solution was 
cooled to ambient temperature, ice cold water (5 mL) was then added and the mixture 
stirred for 20 min. The organic phase was washed with water (10 mL), 5% sodium 
bicarbonate (10 mL), and brine (10 mL), dried and concentrated under reduced pressure. 
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The crude mixture was fractioned on silica gel column using a hexanes/diethyl ether 
gradient to afford both (-)-cannabidiol (0.64 g, 31%) and abn-cannabidiol (0.39 g, 19%). 
Cannabidiol: 1H NMR (300 MHz, CDCl3): δ 6.27 (1H, br s), 6.25 (1H, br s), 6.20 (1H, br 
s), 5.99 (1H, s), 5.58 (1H, s), 4.66 (2H, m), 4.56 (1H, m), 3.85 (1H, dm), 2.45 (2H, t), 
2.21 (1H, m), 2.12 (1H, m), 1.86 (2H, m), 1.80 (3H, s), 1.60 (3H, s), 1.55 (2H, q), 1.31 
(4H, m), 0.88 (3H, t) ppm; 13C NMR (300 MHz, CDCl3): δ 149.5, 143.1, 140.2, 124.2, 
113.9, 110.9, 109.8, 108.1, 46.4, 37.5, 35.8, 31.8, 30.9, 30.7, 28.7, 23.9, 22.8, 20.9, 14.4 
ppm; GC-MS M+ 314 m/z. 
abn-Cannabidiol: 1H NMR (300 MHz, CDCl3): δ 6.22 (1H, d), 6.20 (1H, d), 6.06 (1H, s), 
5.53 (1H, br s), 4.78 (1H, s), 4.65 (1H, t), 4.47 (1H, br s), 3.53 (1H, dm), 2.58 (1H, m), 
2.48 (1H, m), 1.67-2.31 (8H, m), 1.54 (3H, s), 1.47 (2H, m), 1.32 (4H, m), 0.90 (3H, t) 
ppm; 13C NMR (300 MHz, CDCl3) δ 156.5, 154.6, 147.7, 144.1, 139.9, 124.8, 120.1, 
111.6, 108.7, 102.3, 45.2, 40.3, 34.3, 32.2, 31.4, 30.5, 28.4, 23.9, 22.9, 21.6, 14.4 ppm; 
GC-MS M+ 314 m/z. 
 
Synthesis of Codeine-∆9-Tetrahydrocannabinol Codrug.  
 
NO2
O
O
H
N
O
O
MeO
 
 
Codeine-p-nitrophenol Carbonate. All glasswares were oven-dried and cooled 
under a nitrogen atmosphere. Codeine (0.05 g, 0.16 mmol) was placed in a round bottom 
flask under a nitrogen atmosphere and was dissolved in 2 mL of dry chloroform. The 
solution was cooled to 0 °C. DMAP (0.023 g, 0.192 mmol) was then added to the 
solution and the mixture stirred for 5 min. para-Nitrophenylchloroformate (0.037 g, 0.18 
mmol) was dissolved in 3 mL of dry chloroform and the solution was added to the 
reaction mixture drop-wise, the mixture was allowed to warm to the ambient temperature. 
The progress of the reaction was monitored by TLC. After completion of the reaction, the 
73 
 
mixture was diluted with chloroform (15 mL). The chloroform layer was washed 5 times 
with 10 mL 50% NaHCO3 solution and with brine (10 mL), dried over anhydrous sodium 
sulfate and concentrated to afford a solid product (0.032 g, 41 %). 1H NMR (300 MHz, 
CDCl3): δ 8.27 (2H, dd), 7.45 (2H, dd), 6.66 (1H, d), 6.56 (1H, d), 5.70 (1H, dd), 5.52 
(1H, dd), 5.16 (2H, m), 3.82 (3H, s), 3.36 (1H, m), 3.04 (1H, d), 2.75 (1H, m), 2.58 (1H, 
dd), 2.43 (3H, s), 2.36 (1H, dt), 2.29 (1H, dd), 2.03 (1H, dt), 1.88 (1H, d) ppm; 13C NMR 
(300 MHz, CDCl3): δ 156.1, 152.2, 146.7, 145.3, 142.7, 130.4, 127.4, 126.7, 126.6, 
125.6, 122.2, 121.9, 119.9, 115.0, 114.5, 87.4, 72.4, 59.5, 56.9, 46.9, 43.1, 42.6, 40.5, 
35.3, 20.6 ppm; MS (ESI): (M+1) 465 m/z. 
 
 
MeO
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H
O
 
 
Codeine-∆9-Tetrahydrocannabinol Carbonate. All glasswares were oven dried 
and cooled under a nitrogen atmosphere. ∆ 9-THC (0.053 g, 0.17 mmol) was placed in a 
round bottom flask under a nitrogen atmosphere and was dissolved in 2 mL of dry THF. 
The solution was cooled down to 0 °C. NaH (0.09 g, 0.22 mmol) was added to the 
solution and allowed to stir for 5 min. Codeine-p-nitrophenol carbonate (0.078 g, 0.17 
mmol), dissolved in 3 mL of dry THF was added to the reaction mixture drop-wise and 
the mixture was allowed to warm to the ambient temperature. The progress of the 
reaction was monitored by TLC. After the completion of the reaction, the mixture was 
filtered through a pad of celite and then the organic filtrate was concentrated under 
reduced pressure to afford yellow oil. The organic residue was dissolved in chloroform 
(20 mL), the organic layer was washed with 50% sodium bicarbonate solution (3 x 10 
mL), water (10 mL), and brine (10 mL), dried over sodium sulfate and concentrated 
under reduced pressure to afford a brownish solid. The crude product was purified using 
silica gel column chromatography and a methylene chloride-methanol mixture as eluent, 
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to afford the pure product (0.046 g, 43%). 1H NMR (300 MHz, CDCl3): δ 6.71-6.55 (4H, 
m), 6.06 (1H, br s), 5.76 (1H, d), 5.48 (1H, dt), 5.15 (2H, m), 3.93 (3H, s), 3.38 (1H, m), 
3.19 (1H, m), 3.06 (1H, d), 2.74 (1H, m), 2.60-1.29 (27H, m), 1.11 (3H, s), 0.89 (3H, t) 
ppm; 13C NMR (300 MHz, CDCl3): δ 154.5, 152.8, 149.9, 146.9, 143.0, 142.4, 134.9, 
130.6, 129.9, 127.9, 126.9, 126.5, 123.1, 119.5, 115.9, 115.7, 115.0, 114.7, 113.9, 87.9, 
72.2, 59.3, 57.3, 46.9, 45.7, 43.3, 42.9, 40.9, 35.7, 34.4, 31.8, 31.4, 30.8, 27.7, 25.2, 23.6, 
22.8, 20.7, 19.7, 14.4 ppm; MS (ESI): (M+1) 640 m/z; HRMS: calcd. for C40H49NO6 
(M+) m/z 639.3559, found m/z 639.3556. 
 
O
OH
MeO
O
O
H
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Codeine-(-)-Cannabidiol Carbonate Codrug. (-)Cannabidiol (0.175 g, 0.557 
mmol) was placed in a round bottom flask under a nitrogen atmosphere and was 
dissolved in 4 mL of dry THF. The solution was cooled n to 0 °C. NaH (0.028 g, 0.72 
mmol) was added to the solution and allowed to stir for 5 min. Codeine-p-nitrophenol 
carbonate (0.258 g, 0.56 mmol), dissolved in 4 mL of dry THF was added to the reaction 
mixture drop wise and the reaction mixture was allowed to warm to the ambient 
temperature. The progress of the reaction was monitored by TLC. After the completion of 
the reaction, the mixture was filtered through a pad of celite and concentrated under 
reduced pressure. Obtained residue was dissolved in methylene chloride (25 mL), washed 
with 50% sodium bicarbonate solution (3 x 15 mL), water (15 mL), and brine (10 mL), 
dried and concentrated under reduced pressure to afford a crude solid. The crude mixture 
was submitted to silica gel column chromatography using a methylene chloride/methanol 
gradient to afford the pure product (0.164 g, 47%). 1H NMR (300 MHz, CDCl3): δ 6.67 
(1H, d), 6.62 (1H, d), 6.57-6.51 (2H, m), 5.73 (1H, d), 5.56 (1H, s), 5.48 (1H, dt), 5.00 
(1H, dd), 5.09 (1H, m), 4.57 (1H, t), 4.45 (1H, br s), 3.85 (3H, s), 3.78 (1H, dm), 3.39 
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(1H, m), 3.06 (1H, d), 2.76 (1H, m), 1.49-2.64 (23H, m), 1.31 (4H, m), 0.89 (3H, t) ppm; 
13C NMR (300 MHz, CDCl3): δ 155.6, 153.2, 149.7, 147.3, 147.0, 142.9, 142.4, 140.8, 
130.7, 130.1, 127.9, 127.0, 123.7, 119.4, 118.6, 114.8, 114.7, 113.7, 111.7, 88.0, 72.2, 
59.3, 57.2, 46.8, 46.2, 43.3, 43.1, 41.0, 37.8, 35.7, 31.8, 30.8, 30.7, 28.4, 23.9, 22.8, 20.7, 
19.9, 14.4, 14.3 ppm; LC-MS: (M+H)+ 640.4 m/z; HRMS: calcd. for C40H49NO6 (M+) m/z 
639.3559, found m/z 639.3558. 
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Codeine-abn-Cannabidiol Carbonate Codrug. abn-Cannabidiol (0.17 g, 0.54 
mmol) was placed in a round bottom flask under a nitrogen atmosphere and was 
dissolved in 3 mL of dry THF. The solution was cooled to 0 °C. NaH (0.024 g, 0.70 
mmol) was added to the solution and allowed to stir for 5 min. Codeine-p-nitrophenol 
carbonate (0.251 g, 0.55 mmol), dissolved in 3 mL of dry THF was added to the reaction 
mixture drop-wise and the reaction mixture was allowed to warm to ambient temperature. 
The progress of the reaction was monitored by TLC. After the completion of the reaction, 
the mixture was filtered through a pad of celite and concentrated under reduced pressure. 
Obtained residue was dissolved in methylene chloride (25 mL), washed with 50% sodium 
bicarbonate solution (3 x 15 mL), water (15 mL), and brine (10 mL), dried and 
concentrated under reduced pressure to afford the crude solid. The crude mixture was 
subjected to silica gel column using a methylene chloride/methanol gradient to afford a 
pure product (0.13 g, 39%). 1H NMR (500 MHz, CDCl3): δ 6.68 (1H, d), 6.59-6.55 (3H, 
m), 6.15 (1H, s), 5.77 (1H, d), 5.50 (1H, br s), 5.43 (1H, d), 5.20 (1H, d), 5.11 (1H, m), 
4.62 (1H, d), 4.32 (1H, s), 3.87 (3H, s), 3.57 (1H, dm), 3.05 (1H, d), 2.63-1.22 (29H, m), 
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0.87 (3H, t) ppm; 13C NMR (500 MHz, CDCl3): δ 155.03, 153.4, 150.6, 148.9, 146.6, 
144.4, 142.5, 133.6, 130.9, 129.4, 128.2, 126.4, 126.3, 127.7, 119.7, 116.2, 115.4, 110.9, 
109.2, 87.3, 71.1, 59.3, 57.6, 46.9, 45.0, 43.0, 41.8, 40.6, 39.9, 34.9, 34.1, 32.1, 31.1, 
30.3, 28.9, 23.5, 22.7, 21.3, 20.4, 14.3 ppm; LC-MS: (M+H)+ 640.4 m/z; HRMS: calcd. 
for C40H49NO6 (M+) m/z 639.3559, found m/z 639.3543. 
 
 
 
 
Synthesis of 3-O-acetylmorphine-∆9-tetrahydrocannabinol Codrug.  
 
O
O
HO
H
N
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3-O-Acetylmorphine. Morphine free base (1.102 g, 3.87 mmol) was suspended 
in saturated sodium bicarbonate solution (55 mL). To the stirred suspension, 1.1 mL 
(11.68 mmol) of acetic anhydride was added drop-wise. Reaction mixture was stirred at 
ambient temperature and the progress of the reaction was monitored by running TLC. 
After the completion of the reaction, aqueous phase was extracted with chloroform (5 x 
20 mL), dried over sodium sulfate and concentrated under reduced pressure to afford a 
white solid product (1.21 g, 96%). 1H NMR (300 MHz, CDCl3): δ 6.73 (1H, d), 6.60 (1H, 
d), 5.74 (1H, dd), 5.27 (1H, dd), 4.92 (1H, m), 4.16 (1H, m), 3.38 (1H, m), 3.06 (1H, d), 
2.60 (1H, m), 2.54 (1H, dd), 2.43 (3H, s), 2.37 (1H, dt), 2.32 (3H, s), 2.29 (1H, dd), 2.05 
(1H, dt), 1.88 (1H, d) ppm; 13C NMR (300 MHz, CDCl3): δ 168.6, 148.7, 134.2, 132.7, 
132.3, 131.7, 127.8, 121.1, 119.8, 92.5, 66.0, 59.1, 46.0, 43.3, 42.3, 41.6, 35.4, 21.4, 20.9 
ppm; MS (ESI): (M+1) 328 m/z. 
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3-O-Acetylmorphine-p-nitrophenol Carbonate. 3-O-Acetylmorphine (2.0 g, 
6.12 mmol) was placed in a round bottom flask under a nitrogen atmosphere and was 
dissolved in dry chloroform (10 mL). The solution was cooled to 0 °C. DMAP (0.9 g, 
7.34 mmol) was added to the solution and allowed to stir for 5 min. p-
Nitrophenylchloroformate (1.48 g, 7.34 mmol) dissolved in dry chloroform (8 mL) was 
added to the reaction mixture drop-wise and the reaction mixture was stirred at 0 °C. 
Progress of the reaction was monitored by running TLC. After the completion of the 
reaction, the mixture was diluted with chloroform (20 mL). The chloroform layer was 
washed 5 times with 25 mL 50% NaHCO3 solution and with brine (20 mL), dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to afford a solid 
product (1.35 g, 45 %). 1H NMR (300 MHz, CDCl3): δ 8.30 (2H, dd), 7.51 (2H, dd), 6.82 
(1H, d), 6.64 (1H, d), 5.71 (1H, dd), 5.58 (1H, dd), 5.24 (1H, m), 5.19 (1H, m), 3.42 (1H, 
m), 3.09 (1H, d), 2.80 (1H, m), 2.62 (1H, dd), 2.45 (3H, s), 2.41 (1H, dt), 2.19 (3H, s), 
2.09 (1H, dt), 1.92 (1H, d) ppm; 13C NMR (300 MHz, CDCl3): δ 168.5, 155.9, 151.8, 
149.2, 145.6, 132.2, 131.9, 130.4, 127.8, 126.4, 125.5, 122.3, 122.2, 121.8, 119.9, 113.8, 
88.2, 72.6, 59.1, 46.7, 43.8, 42.9, 40.7, 35.3, 21.0, 20.8 ppm; MS (ESI): (M+1) 493 m/z. 
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3-O-Acetylmorphine-∆9-Tetrahydrocannabinol Carbonate Codrug. ∆9-THC 
(0.053 g, 0.17 mmol) was placed in a round bottom flask under a nitrogen atmosphere 
and was then dissolved in 2 mL of dry THF. The solution was cooled to 0 °C. NaH (0.09 
g, 0.22 mmol) was added to the solution and allowed to stir for 5 min. 3-O-
Acetylmorphine-p-nitrophenol carbonate (0.083 g, 0.17 mmol), dissolved in 3 mL of dry 
THF was added to the reaction mixture drop-wise and the reaction mixture was allowed 
to warm to the ambient temperature. The progress of the reaction was monitored by TLC. 
After the completion of the reaction, the mixture was filtered through a pad of celite and 
concentrated under reduced pressure. Obtained residue was dissolved in methylene 
chloride (20 mL), washed with 50% sodium bicarbonate solution (3 x 10 mL), water (10 
mL), and brine (10 mL), dried and concentrated under reduced pressure to afford the 
crude solid. The crude mixture was subjected to silica gel column using a methylene 
chloride/methanol gradient to afford a pure product (0.057 g, 51%). 1H NMR (500 MHz, 
CDCl3): δ 6.81 (1H, d), 6.61 (1H, d), 6.59 (1H, d), 6.55 (1H, d), 6.07 (1H, br s), 5.75 (1H, 
d), 5.47 (1H, dt), 5.22 (1H, d), 5.13 (1H, m), 3.40 (1H, m), 3.19 (1H, d), 3.09 (1H, d), 
2.75 (1H, m), 2.60 (1H, dd), 2.52 (2H, t), 2.45 (3H, s), 2.39 (1H, dt), 2.32-1.66 (11H, m), 
1.65 (3H, s), 1.59 (2H, m), 1.42 (3H, s), 1.32 (4H, m), 1.11 (3H, s), 0.89 (3H, t) ppm; 13C 
NMR (500 MHz, CDCl3): δ 168.7, 154.7, 152.9, 149.9, 143.0, 135.1, 132.4, 132.2, 131.6, 
130.1, 123.2, 123.1, 122.3, 119.6, 115.6, 115.1, 113.9, 113.7, 88.7, 72.2, 59.1, 45.6, 43.3, 
43.2, 41.1, 40.9, 35.6, 35.5, 34.3, 34.2, 31.7, 31.3, 30.7, 27.7, 25.1, 23.5, 22.7, 20.9, 20.8, 
19.5, 14.3 ppm; MS (ESI): (M+1) 668 m/z; HRMS: calcd. for C41H49NO7 (M+) m/z 
667.3508, found m/z 667.3508. 
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Chapter 3 
The Analgesic activities of Codrugs and their Parent Compounds 
 
3.1 Introduction 
 
It is easier to design and synthesize more efficient pain modulating drugs if the 
type of pain can be better understood. Pain can arise from tissue damage (nociceptive) or 
from injury to the nervous system (neuropathic). Nociception refers to a withdrawal 
behavior in response to a dangerous (e.g. sharp or hot) environmental stimulus (Joshi and 
Honore, 2006). Nociceptive pain occurs when the nociceptive system gets activated by 
noxious stimuli that can cause mechanically-, chemically-, or thermally-induced damage 
to tissues (Woolf, 2004; Woolf and Salter, 2000). The nociceptive system originates in 
peripheral tissues, spans the spinal cord, traverses the brain stem and thalamus, and 
terminates in the cerebral cortex, where the sensation of pain is perceived. Peripheral 
tissues are innervated by nociceptors, highly specialized primary sensory neurons, which 
contain specific receptors or ion channels at their peripheral terminals (Woolf, 2004; 
Woolf and Salter, 2000). The A-delta fiber and the C-fiber nociceptors are the two main 
classes of nociceptors. C-fibers are the most common; about 70% of all nociceptors are of 
the C-fiber type. Activation of these receptors or ion channels by noxious stimuli 
generates a depolarizing current (or an action potential, or an electrical impulse), which is 
then relayed to the brain for pain perception (Fig. 3.1) (Scholz and Woolf, 2002). This 
pain is well localized, and is characterized as dull or aching.  
 
The A-delta fiber and the C-fiber nociceptors are the 2 main classes of 
nociceptors. C-fibers are the most common; about 70% of all nociceptors are of the C-
fiber type.  
Neuropathic pain arises from injury to, or abnormal function of the nervous 
system. The pain can occur even without any physical or chemical stimuli. Unlike 
nociceptive pain, neuropathic pain can persist for a long time, even after the initiating 
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injury has been completely healed. This leads to abnormal processing of sensory 
information by the nervous system. After the nerve injury, changes occurring in the 
central nervous system can persist indefinitely. Examples of neuropathic pain are: 
phantom limb syndrome, diabetic pain, shingles, herpes zoster, pain associated with HIV 
infections, and pain experienced after chemotherapy. The pain is felt in many different 
ways, such as burning, tingling, prickling, shooting, and spasm (Rotha et al., 1998).  
Allodynia and hyperalgesia are two hallmarks of neuropathic pain. Allodynia refers to 
pain due to a stimulus, which does not normally provoke pain e.g., touch, cold, light 
pressure can be felt as pain.  Hyperalgesia refers to an increased response to a stimulus, 
which is normally painful.  
 
 
   
 
Fig. 3.1 Nociceptive pain transmission  (Rotha et al., 1998; Reprinted by 
permission) 
 
 Different animal pain models are used for different kinds of pain. For example 
models developed to measure responses to acute noxious thermal stimuli use a noxious 
heat or cold stimulus to the paw or tail of rodents. These models are widely used for 
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testing opioid analgesics. In these methods, latency to behavioral response is recorded 
and a cut-off time period is set to avoid any tissue damage to the animal. In the tail-flick 
test, an intense beam of light is applied to the tail of a rat and the latency period is 
measured until the tail is flicked out of the path of the light beam (Fig. 3.2). One other 
assay to determine sensitivity to heat in normal animals, as well as in animals under 
chronic pain conditions, has been described by Hargreaves et al. and uses a radiant heat 
source. In this method, the temperature of the heat source is applied to the hind paw and 
increases over time until it reaches a painful threshold. Latency to of pain to the hind paw 
is recorded and analyzed. One widely used method to test for reactivity to cold is the 
application of a drop of cold acetone onto the skin of a rat. Acetone produces a distinct 
kind of sensation when it evaporates. Normal rats do not respond to this stimulus, while 
nerve-injured rats show an exaggerated response.  
    
 
    
 
 
                 
 
 
Fig. 3.2 The Tail-Flick test (Reprinted by permission) 
 Responses to acute noxious mechanical stimuli are measured by stimulating the 
paw or the tail of rodents. In the Randall Selitto test, increased pressure is applied to the 
dorsal surface of the hind paw/tail of a rat via a dome-shaped plastic tip. The threshold 
(in grams) for either paw or tail withdrawal is then recorded.  Similarly, responses to 
acute noxious chemical stimuli can be measured by injecting chemical irritants such as 
capsaicin, formalin or mustard oil. The animal responds by biting or licking the injected 
82 
 
paw. These observations are recorded at various time points after administration of the 
drug to be tested.  
Different models are used for pain following injury to the nervous system. For 
example, the chronic constriction injury pain model (Bennett’s model). This pain model 
involves the tying of four loose ligatures around the sciatic nerve of a rat, just tightly 
enough to touch the nerve (Fig. 3.3) (Expert Rev Proteomics, 2008, Expert Review Ltd.).  
Subsequent swelling of the nerve constricts the nerve, which develops hyperalgesia and 
allodynia over 10 to 14 days (Hogon, 2002).  
 
Fig. 3.3 The Chronic Constriction Injury pain model showing tying of four loose ligatures 
around the sciatic nerve (Expert Rev Proteomics, 2008, Expert Review Ltd., reprinted by 
permission) 
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One other most studied neuropathic pain model is L5-L6 spinal nerve ligation 
(SNL; Chung’s model). In this ligation process, the L5 and L6 spinal nerves of the animal 
are isolated and tightly ligated with silk thread. This induces mechanical allodynia within 
7-10 days. Models have also been developed involving cold allodynia and thermal 
hyperalgesia. Animals exhibit a dynamic mechanical allodynia, which is assessed by 
gently brushing with a soft brush. In the present chapter, the tail-flick test is used to 
assess the affect of codrugs on nociceptive pain and the chronic constriction injury pain 
model is used to assess the effect of codrugs on neuropathic pain.  
 
Codeine is a well known opioid drug commonly used to control pain, whether 
alone or in combination with an adjunct drug. It produces full efficacy in the tail-flick test 
for antinociception. Unfortunately, long term use of these types of drugs results in the 
development of tolerance and physical dependence. This reduces the analgesic effects 
necessitating the administration of high and potentially harmful doses to achieve effective 
pain control. The efficacies of physical mixtures of opioids non-antinociceptive doses of 
cannabinoids have been previously been characterized in rodent models of nociceptive 
and neuropathic pain (Smith et al., 1998; Cichewicz et al; 2002). These models included 
acute thermal nociception and peripheral neuropathy (chronic constriction nerve injury, 
CCI). In the present chapter, we have investigated codrug therapy where two drugs, 
codeine and Δ9-THC are administered as a single chemical entity, whereby the two 
molecules are covalently linked together via a carbonate ester linkage (Cod-THC). The 
efficacies of each of the parent drugs as well as a 1:1 physical mixture of the parent 
drugs, codeine and Δ9-THC were compared with the Cod-THC codrug as pain 
modulators in the above pain models to determine their relative effectiveness. Similarly, a 
codeine-cannabidiol (Cod-CBD) codrug was also assessed for its analgesic activity and 
this activity compared to the individual parent drugs.  
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3.2 Methods and Materials 
 
3.2.1 Animals 
 
 Male Sprague-Dawley rats (Harlan, Indianapolis) about 90 days old, weighing 
300-350 g were used for all experiments. Rats were housed separately in a transparent 
cage; with free access to standard laboratory chow and tap water in a humidity- and 
temperature-controlled facility with lights on between 0600 and 1800 h. Rats were 
trained in the test situation before initiation of the experimental procedures. Rats were 
fasted overnight before oral administration of drug. Body weights were determined on the 
day of experimentation. At the end of the experiment, rats were euthanized with 
pentobarbital sodium (150 mg/kg, intraperitoneal, IP). A crossover paradigm was used 
within an experiment (if possible) to minimize the number of rats. All testing was 
performed in accordance with the guidelines of the National Institute of Health Guide for 
Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985). The protocol 
was approved by the University of Kentucky Animal Care and Use Committee.  
 
3.2.2 Drugs 
 
The Cod-THC codrug was evaluated using tail-flick and chronic constriction 
injury pain model. The parent drugs codeine, Δ9-THC and 1:1 physical mixture of 
codeine and Δ9-THC were also assessed using the same pain models. Similarly, Cod-
CBD codrug, codeine and cannabidiol parent drugs were evaluated using tail-flick pain 
model. Drugs were dissolved in 15% PEG saline solution and administered by the oral 
route using a gavage feeding needle after overnight fasting of the animals. A 15% 
solution of PEG in saline (vehicle) served as the control. 
 
3.2.3 Tail Flick test (Measure of analgesia/antinociception) 
 
  The tail-flick test primarily assesses the spinal antinociceptive (pain relief) 
response to noxious thermal stimuli (D’Amour and Smith, 1941). An intense beam of 
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light is applied to the tail of a Sprague-Dawley rat and the latency period is measured 
until the tail is flicked out of the path of the light beam (Fig. 3.2). Baseline tail-flick 
latencies were determined prior to drug administration using the tail-flick latency test. 
During testing, a cutoff time of 10 s was employed to prevent damage to the tail of the 
rat.  
 
First, rats (6/group) were treated with codeine alone (10 mg/kg), and then with the 
Cod-THC codrug (10 mg/kg). Drugs were administered via the oral route. Tail flick 
latencies (TFL) were measured before and after the drug was given. The latency period is 
the time from onset of stimulation to a rapid flick/withdrawl of the tail from heat source. 
This time period is also measured before the drug is given to ensure the analgesic effect. 
Therefore, responsiveness (TFL) was measured prior to (5, 10, 15, and 30 min. apart) and 
at after oral dosing (Fig. 3.4). Only one dose of codrug was initially examined to confirm 
the presence of an analgesic action of the codrug. This effect of a single dose of the Cod-
THC codrug was compared with the parent drug codeine, to compare the relative 
analgesic effects of these two drugs.  
 
Second, rats (6/group) were treated with codeine alone (10 mg/kg), and with three 
doses (5, 10 and 20 mg/kg) of the Cod-THC codrug. Drugs were administered via the 
oral route. Animals were tested for tail-flick response using the tail-flick apparatus. 
Intensity of the heat source was adjusted to produce tail-flick latencies of 3 to 4 sec. 
These baseline latencies of the rats were recorded three times (5, 10, 15, 30 min apart). 
Responsiveness (TFL) was measured thrice again after oral dosing (5, 10, 15, 30 min 
apart). Dose response curves can be generated if minimum of three doses of a drug are 
utilized in this assay. The time-response graphs obtained with the three different doses of 
codeine-THC codrug are illustrated in Fig. 3.5 and are compared with that of the 10 
mg/kg codeine dose.  
 
Third, rats (6/group) were treated with three doses (5, 10 and 20 mg/kg) of 
codeine administered via the oral route. Responsiveness (TFL) was measured prior to 
(baseline) and thrice (5, 10, 15, 30 min. apart) after oral dosing as described earlier. 
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Time-response and dose-response curves were drawn to calculate ED50 values for both 
codeine and the Cod-THC codrug (Fig. 3.7). 
 
In a similar manner, the codeine-cannabidiol codrug (Cod-CBD) and its parent 
drugs codeine and cannabidiol were assessed in the tail-flick test. Rats (6/group) were 
treated with codeine alone (10 mg/kg), with cannabidiol alone (10 mg/kg) and with three 
doses (5, 10 and 20 mg/kg) of Cod-CBD codrug (Fig. 3.14). 
 
3.2.4 Chronic Constriction nerve injury (CCI, Neuropathic pain model)  
 
Surgery 
 
 The rodent model of peripheral neuropathy (chronic constriction nerve injury, 
CCI) (Bennett and Xie, 1988) was used to characterize the antihyperalgesic effect of 
codeine and with the codeine-Δ9-THC codrug. This pain model involves the tying of four 
loose ligatures around the sciatic nerve, which results in the development of mechanical 
(tactile) allodynia in the ipsilateral hindpaw of the rat.  
 
Mechanical hyperalgesia 
 
Enhanced sensitivity to mechanical noxious stimuli (mechanical hyperalgesia) 
was evaluated using the paw pressure test (Randall and Selitto, 1957). This was done 
prior to surgery (pre-CCI baseline) and on the post-surgery day. The hind paw was placed 
between a blunt pointer and a flat surface and increasing pressure was applied to the 
dorsal side of the paw. Rats (6/group) were treated with codeine alone (4.9, 10, 20, 40 
mg/kg doses), Δ9-THC alone (5.1 mg/kg dose) and Cod-THC codrug (2.5, 5 and 10 
mg/kg doses). Drugs were administered via the oral route.  
 
3.2.5 Statistical analysis 
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 Responses were normalized for baseline values. Percent maximum possible effect 
was calculated at the time of peak response: %MPE = (TFL-baseline)/ (cut-off-baseline) 
* 100. ED50 values were computed for Cod-THC codrug and codeine. The overall effects 
(antihyperalgesia) were presented as areas-under-the-time curves, calculated by the 
trapezoidal rule for baseline normalized responses. Data were analyzed using regression 
analysis, analysis of variance (ANOVA), post-hoc Student Newman Keuls test (SNK) 
and t-test. Level of significance was P≤0.05. All data were mean ± SEM (n = number of 
rats). 
  
3.3 Results 
 
3.3.1 Cod-THC codrug antinociception (tail flick tests) 
 
 The antinociceptive effects of codeine alone and various doses of Cod-THC 
codrug were characterized after the oral administration in the tail-flick test. The present 
data provides evidence (Figs. 3.4, 3.5, 3.6, 3.7, 3.8) that a codrug consisting of codeine 
(low dose) and Δ9-THC (non-effective dose) significantly enhances codeine effectiveness 
against acute nociception. In preliminary experiments, one dose of Cod-THC codrug and 
one dose of codeine were given to the rats to check and compare the analgesic effect of 
the Cod-THC codrug with codeine. A 10 mg/kg dose of Cod-THC codrug and a 10 
mg/kg codeine dose were chosen for this purpose (Fig. 3.4). Codeine and Cod-THC 
codrug tail-flick latency values were above baseline values, which indicate that both 
drugs exhibit an analgesic effect. On comparing the effect of codeine with the Cod-THC 
codrug, it can be observed that the analgesic effect of the codrug is much greater than that 
of codeine. Next, the time-response curve for three doses of the Cod-THC codrug (5, 10, 
20 mg/kg) was generated to obtain a dose-response curve. Figs. 3.5 and 3.6 illustrate the 
time-response curve for the 5, 10, 20 mg/kg doses. In Fig. 3.5, the three doses of Cod-
THC codrug were compared with codeine (10mg/kg) and in Fig. 3.6 the time-response 
curve for the three doses of the Cod-THC codrug is shown.  Table 3.1 reports the area- 
under-the-curve (AUC) values for all the three doses of the Cod-THC codrug.  
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It can be seen that as the dose of the Cod-THC codrug is increased, the AUC also 
increases. This indicates that the drug exhibits a dose-response curve (Dose: F5,23= 11.1, 
P<0.0005). F5,23= 11.1 indicates that the codrug is exhibiting a dose-response effect and 
the P<0.0005 value proves the statistical significance of the data between each increasing 
dose. Post-hoc Student Newman Keuls (SNK) analysis indicates that the 10 and 20 mg/kg 
dose showed a significant analgesic effect when compared to vehicle alone (P<0.05). The 
maximum analgesic effect was observed after 15 minutes with the 10 mg/kg dose, and 
after two hours with the 20 mg/kg dose of the Cod-THC codrug. This unusual result 
could be due to a solubility issue with the higher dose of codrug in the vehicle. The drug 
may be precipitating out in the gastrointestinal tract, probably in the stomach, after oral 
administration and then slowly dissolves as it passes through the gastrointestinal tract.  
 
 
 
 
 
 
 
 
 
                 
 
 
 
 
 
Fig. 3.4 Tail-Flick Latencies for Codeine and Cod-THC Codrug  
 
 
 
 
89 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 3.5 Antinociceptive Effect of Codeine and Cod-THC Codrug (5, 10, 20 mg/kg doses)  
in the Tail-Flick Pain Model 
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       Fig. 3.6 Time-response Curves for the Cod-THC Codrug in theTail-Flick Test 
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Fig. 3.7 Time-response (a) and dose-response (b) curves for Codeine in the Tail-Flick      
Model 
    
(a) 
(b) 
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                 Table 3.1 AUCs for 5, 10, and 20 mg/kg doses of Cod-THC Codrug 
 
Cod-THC Codrug dose AUC0-240 min. (s * min) 
5 mg/kg 190.5 ± 34.9 
10 mg/kg 747.6 ± 144.6 
20 mg/kg 1025 ± 171.1 
Vehicle 8.5 ± 1.7 
  
 
Fig. 3.8 illustrates the %MPE (Maximum Possible Effect) for the Cod-THC 
codrug and for codeine. % MPE can be related to the effectiveness of the drug. The 
greater the %MPE, the more effective the drug is. The highest %MPE achieved by 
codeine and the Cod-THC codrug is 70%. Increasing the dose further for both codeine 
and the Cod-THC codrug does not result in a further increase in the %MPE. The 20 
mg/kg dose of the Cod-THC codrug produced the highest %MPE. The equi-effective 
dose of codeine was 40 mg/kg compared to a 20 mg/kg dose of the Cod-THC codrug. 
The 20 mg/kg dose of the Cod-THC codrug contains 9.8 mg/kg dose of codeine. 
Therefore, the analgesic effect shown by 9.8 mg/kg dose of codeine when given in the 
form of the Cod-THC codrug is equivalent to a 40 mg/kg dose of codeine alone. In 
conclusion, the present data demonstrates that combining codeine with Δ9-THC in the 
form of a codrug may enhance codeine effectiveness against acute nociception by 
decreasing the side effects associated with higher doses of codeine. 
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Fig. 3.8 Dose-Response Curves for the Antinociceptive Effects of the Codeine-THC 
Codrug and Codeine Alone in the Tail-Flick Test 
 
 
3.3.2 Cod-THC codrug Antihyperalgesic effect (CCI model) 
 
Chronic constriction nerve injury (CCI) results in significantly decreased 
thresholds to mechanical noxious stimuli (hyperalgesia) compared to the pre-surgical 
threshold. The paw withdrawal threshold (PWT) (pre-CCI) was 225 ± 3.5 g versus a 
PWT (post-CCI) of 112 ± 4.3 g. The antihyperalgesic effect of codeine alone, Δ9-THC 
alone and various doses of the Cod-THC codrug were characterized after administration 
via the oral route. The data obtained provides evidence (Figs. 3.9, 3.10, 3.11, 3.12, 3.13) 
that the Cod-THC codrug exhibits a synergistic antihyperalgesic effect. Fig. 3.9 
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demonstrates the time-response and dose-response curves for various doses of codeine 
alone (4.9, 10, 20, 40 mg/kg). Dose-response curves for codeine were generated to 
determine the dose of codeine that was equi-effective as the Cod-THC codrug. 65%MPE 
was exhibited by codeine. Figs. 3.10 and 3.11 show the time-response curves for various 
doses of the Cod-THC codrug (Dose: F5,23= 6.8, P<0.005). F5,23= 6.8 indicates that the 
codrug is exhibiting a dose-response effect and the  P<0.005 value proves the statistical 
significance of the data. Post-hoc Student Newman Keuls (SNK) analysis indicates that 
the 5 and 10 mg/kg doses of the codrug showed an enhanced antihyperalgesic effect 
when compared to vehicle alone.  The maximum possible effect was achieved around 1.7 
hours post-dosing with the 5 mg/kg dose of the Cod-THC codrug, and at 3.5 hours post-
dosing with the 20 mg/kg codrug dose. The enhancement of the analgesic response is 
evident at several points in the time-response curves, as well as in the overall effect 
(AUC) (Table 3.2).  
 
 The bar graph illustrated in Figs. 3.12, 3.13 indicate that the antihyperalgesic 
effect of the Cod-THC codrug is much more than just an additive effect of the two parent 
drugs. Both codeine and Δ9-THC at doses (4.9 mg/kg and 5.1 mg/kg) that did not produce 
a significant effects of their own, afforded an enhanced antihyperalgesic effect when each 
drug was incorporated into the Cod-THC codrug in their molar amounts(10 mg/kg Cod-
THC codrug) (Fig. 3.11). One must consider the benefits of a synergistic relationship 
over an additive interaction. Additivity simply represents the addition of the expected 
effects of each dose of drug alone, whereas synergy describes a situation in which the 
combined effect greatly exceeds the expected simple addition. Clearly, synergistic drug 
interactions would be more significant, indicating that low doses of two drugs covalently 
tethered together in a codrug molecule could produce effects of high magnitude. The 
clinical benefits of such an enhancement can be easily imagined, as it would allow for the 
administration of much lower drug doses, which would still yield a potent analgesic 
effect yet hopefully induce fewer side effects. This is the first report of a synergistic 
interaction between Δ9-THC and codeine after administration of a Cod-THC codrug, 
since previous studies have only examined the physical mixtures of these two drugs. 
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Fig. 3.9 (a)Time-response  curve for Codeine in the CCI model 
 
 
 
(a) 
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Fig. 3.9 (b) Dose-response curve for Codeine in the CCI model 
 
 
 
 
 
 
 
 
(b) 
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Fig. 3.10 Antihyperalgesic effect of the Cod-THC codrug in the CCI Model 
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Fig. 3.11 Time-Action Curves for the Cod-THC Codrug in the Chronic Constriction 
Nerve Injury (CCI) Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.12 Antihyperalgesic Effect of the Cod-THC Codrug in the Chronic Constrictive 
Nerve Injury (CCI) Model 
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Fig.  3.13 Antihyperalgesic Effect of Codeine, THC and the Cod-THC Codrug in the 
Chronic Constriction Nerve Injury (CCI) Model 
 
 
Table 3.2 AUCs for 2.5, 5, and 10 mg/kg Cod-THC Codrug (CCI model) 
 
Cod-THC Codrug dose (mg/kg) AUC0-180 min. (g * min) 
2.5 1925 ± 808.7 
5 6406.3 ± 1663.9 
10 9387.5 ± 2384.8 
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3.3.3 ED50 values 
 
  The dose of a drug that is pharmacologically effective for 50% of the population 
exposed to the drug, or that shows a 50% response in a biological system that is exposed 
to the drug is defined as the ED50 value of the drug. As can be seen in Table 3.3, the ED50 
value for the Cod-THC codrug in the Tail-flick test, as well as in the CCI pain model is 
much lower than the ED50 value of codeine in either test, which suggests that the use of a 
low dose combination of these two analgesics in a codrug structure is a valid and 
effective approach for improved treatment of pain. 
 
 
 
         Table 3.3 ED50 values for the Cod-THC codrug and codeine  
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ED50 = 6.42 mg/kg(Tail-flick)             
          = (0.01 mmol/kg) 
 
          = 3.99 mg/kg (CCI) 
          =(0.0062 mmol/kg) 
 
ED50 = 12.5 mg/kg (Tail-flick) 
          = 0.042 mmol/kg 
 
          = 13.5 mg/kg (CCI) 
          =(0.045 mmol/kg) 
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3.3.4 Codeine-cannabidiol (Cod-CBD) codrug antinociception (tail flick test) 
 
 The antinociceptive effects of codeine alone (10 mg/kg), cannabidiol alone (10 
mg/kg) and various doses of the Cod-CBD codrug (5, 10 and 20 mg/kg) were evaluated 
after oral administration in the Tail-flick test (Fig. 3.14, 3.15). Cannabidiol was chosen 
because it is a non-psychoactive cannabinoid. Fig. 3.14 shows the dose-response curve 
for the antinociceptive effect of the Cod-CBD codrug. The graph illustrates that 10 and 
20 mg/kg doses of the Cod-CBD codrug exhibit an antinociceptive effect. A 10 mg/kg 
dose of codeine shows 30 %MPE, while a10 mg/kg dose of cannabidiol shows 40 %MPE 
in the Tail-flick test. When given in the form of the Cod-CBD codrug, the %MPE 
produced by the 20 mg/kg dose is 70 %. This is an example of additive effect rather than 
synergistic effect (Fig. 3.15). The opioid dose can still be reduced even with the additive 
effect shown by the Cod-CBD codrug since less codeine is needed to show the same 
effect when given in conjugation with cannabidiol. 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 Fig. 3.14 Time-Response Curves for the Cod-CBD Codrug in the Tail-Flick Test 
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Fig. 3.15 Antinociceptive Effects of Codeine, Cannabidiol and the Cod-CBD Codrug in 
the Tail-Flick Test 
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Chapter 4 
In-vitro Stability Study of the Cod-THC Codrug 
 
4.1 Introduction  
 
Compounds in drug discovery encounter a wide range of pHs when administered 
to patients. Oral dosing exposes compounds to pH 1 to 2 in the stomach, pH 4.5 at the 
beginning of the small intestine, pH 6.6 as an average pH for the small intestine, and pH 
5 to 9 in the colon. The mean fasting stomach pH of an adult is approximately 2, and 
increases to 4-5 following ingestion of food. These are useful pHs for in vitro evaluation 
of the chemical stability of a drug candidate as it passes through the gastrointestinal tract 
(Kern and Di 2008). 
 
Important insights can be obtained by studying the stability of the drug with 
simulated gastrointestinal fluids. These include simulated gastric fluid (SGF) and 
simulated intestinal fluid (SIF) (Piper et al., 1963; DeBeer et al., 1935). The recipe of 
preparing these gastrointestinal fluids are specified in the United States Pharmacopeia 
(USP) and described in chapter 1. The prime object of performing stability study of a 
drug in nonenzymatic and enzymatic assays is to predict stability of the drug in 
gastrointestinal tract after oral dosing. The obtained stability results can guide the 
structural modification of the drug to improve gastrointestinal stability for increasing 
bioavailability and for prioritization of compounds for subsequent in vivo 
pharmacokinetic studies (Patrick, 1995).  
 
Blood contains a large number of hydrolytic enzymes such as cholinesterase, 
aldolase, lipase, dehydropeptidase, and alkaline and acid phosphatase. If the drug has a 
labile moiety, sensitive to one of these enzymes, it can be decomposed in the plasma. 
Many such enzyme sensitive groups are used to enhance the compound’s 
pharmacological activity at the target protein. Rapid hydrolysis in plasma can be a major 
cause of a compound’s rapid clearance, and pharmacologically efficacious concentrations 
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may not be achievable in vivo if this occurs. Exceptions are the issue of a prodrug or a 
codrug, which requires hydrolysis in plasma to produce the active parent drug(s). Prodrug 
strategy is mainly utilized to improve absorption of the prodrug from the gastrointestinal 
tract, since the prodrug will be designed to enhance gastrointestinal absorption by 
improvement on physicochemical properties compared to the parent drug. Similarly in a 
codrug strategy gastrointestinal absorption of the two parent drugs can be improved. 
Once in the plasma, the codrug is designed to be rapidly hydrolyzed to afford the parent 
compounds. Therefore, before the in vivo study of the codrug is performed, plasma 
stability data must be generated to determine if the codrug is stable in the gastrointestinal 
tract (Kern and Di 2008). 
 
With the aim of improving the oral bioavailability of the parent drugs codeine and 
Δ9-THC, the codrug Cod-THC was initially evaluated for its stability in buffers ranging 
from pH 1 to pH 9 (Waterman et al., 2002), as well as in SGF, SIF, and rat plasma and 
brain. The following experiments were performed in aqueous solutions to model drug 
barriers: 
 
• pH : Aqueous buffers (37 ºC, pH 1-9) 
• GI : Simulated gastric fluid (USP, 37 ºC) 
• GI : Simulated intestinal fluid (USP, 37 ºC) 
• Plasma : Rat plasma (37 ºC) 
• Brain : Brain homogenate (37 ºC)  
 
The molecular weight of the Cod-THC codrug is 639 g/mole. Since this value is 
above 500, the molecule might not cross the blood-brain barrier, but this cannot be 
concluded before carrying out the pharmacokinetic study of the Cod-THC codrug. If 
the codrug does cross the blood-brain barrier, then it is important to determine its 
stability in brain homogenate, to determine if it can be hydrolyzed by brain enzymes 
to release the parent drugs. Thus, a stability study of the Cod-THC codrug was also 
carried out in rat brain homogenate.  
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4.2 Materials and Methods 
 
4.2.1 Drugs 
 The Cod-THC codrug and Δ9-THC were synthesized in the laboratory via the 
procedures reported in Chapter 2.  
 
4.2.2 Sample preparation 
 
Standard curve and quality control validation solutions:  
 
 Stock solutions of Cod-Δ9-THC, codeine, Δ9-THC and the internal standard (2-
methoxynaphthalene) were prepared in methanol. A standard curve with eight points was 
prepared and utilized in the quantitative analysis of the unknown samples. Standard curve 
samples were prepared by spiking blank plasma/buffers/brain homogenate with Cod-
THC, Codeine, or Δ9-THC working solutions. Calibration curves were obtained using 
quadratic least-squares regression of area-under-the-curve (AUC) ratios (analyte peak 
AUC/internal standard peak AUC) versus drug concentrations. The amount of codrug, or 
parent drugs, was then determined using the standard curves.  
 
Kinetics of hydrolysis of the codrug in aqueous solutions (non-enzymatic):  
 
 A 0.02 M hydrochloric acid buffer, pH 1.3, as a non-enzymatic simulated gastric 
fluid; a 0.02 M sodium phthalate buffer, pH 5.2; a 0.02 M phosphate buffer, pH 7.4; and 
a 0.02 M boric acid and potassium chloride buffer, pH 9.7 was used in this study. The pH 
5.2 simulates intestinal fluid and the pH 7.4 simulates rat plasma. pH 9.7 was utililized to 
check the chemical stability of the carbonate bond present in Cod-THC codrug. Reactions 
were initiated by adding 5mL of 1.0*10-3 M stock solution (in methanol) of the Cod-
THC codrug to 5 mL of appropriate thermostated (37 ± 0.5 oC) aqueous solutions of the 
above buffer species. Aliquot-parts (300 µL) were removed from the codrug-buffer 
solutions at various time intervals, mixed with 50 µL of the 0.01M internal standard 
solution (2-methoxynaphathalene) and 20 µL of the resulting solution was immediately 
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injected onto the HPLC-DAD analytical system for quantitative analysis.  Experiments 
were run in triplicate (Omar, 1998).  
 
Kinetics of hydrolysis of the codrug in simulated gastric fluid (SGF) and simulated 
intestinal fluid (SIF) (enzymatic conditions): 
 
Reactions were initiated by adding 5mL of 1.5*10-3 M stock solution (in 
methanol) of the Cod-THC codrug to 5 mL of appropriate thermostated (37 ± 0.5 oC) 
SGF and SIF solutions. Aliquot-parts (300 µL) of the resulting solutions were removed at 
various time intervals, mixed with 50 µL of the 0.01M internal standard solution (2-
methoxynaphathalene) and immediately analyzed by HPLC-DAD.   Experiments were 
run in triplicate.  
 
Kinetics of hydrolysis of the codrug in rat plasma (in vitro):  
 
Plasma from male Sprague-Dawley rats was obtained by centrifugation of blood 
samples at 12000 rpm for 10-15 min. The supernatant plasma fractions (2 mL) were 
diluted with phosphate buffer to afford a total volume of 2.5 mL (80% rat plasma). 
Incubations were performed at 37 ± 0.5 oC in a water-bath with constant stirring. 
Reactions were initiated by adding 100 µL of the Cod-THC codrug stock solution (0.06 
M in methanol) to 2.5 mL of preheated (37oC) 80% rat plasma. Aliquot-parts (100 µL) 
were removed at various times, mixed with 50 µL of the 0.01M internal standard solution 
(2-methoxynaphathalene in methanol) and then deproteinized by mixing with 600 µL of 
acetonitrile. After centrifugation for 10 minutes at 12,000 rpm, the supernatant was 
separated, dried under nitrogen gas, the residue reconstituted with 300 µL of methanol, 
and the resulting solution was analyzed by HPLC-DAD.  
 
Kinetics of hydrolysis of the codrug in rat brain homogenate: 
 
Brain homogenate obtained from male Sprague-Dawley rats was obtained by 
homogenizing brain tissues with 3 volumes of 1.15% KCl/g brain tissue for 2 minutes in 
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a tissue homogenizer. Incubations were performed at 37 ± 0.5 oC in a water-bath with 
constant stirring. The reactions were initiated by adding 100 µL of the codrug stock 
solution (0.06 M in methanol) to 2.5 mL of preheated (37oC) brain homogenate. Aliquot-
parts (100 µL) were removed at various times, mixed with 50 µL of the 0.01M internal 
standard solution (2-methoxynaphathalene in methanol) and deproteinized by mixing 
with 600 µL of acetonitrile. After centrifugation for 10 minutes at 12,000 rpm, the 
supernatant was separated, dried under nitrogen gas, the residue reconstituted with 300 
µL of methanol, and the resulting solution analyzed by HPLC-DAD.  
 
 
4.2.3 HPLC analysis 
 
HPLC analysis was carried out with an Agilent 1100 series Quatpump, equipped 
with a photodiode array detector and a computer integrating apparatus. A Waters 
Symmetry ® C18 (5 µm, 3.9 x 150 mm) column protected with guard column (Nova-
Pak® C18; 3.9 x 20 mm; 4µ) was used as the stationary phase; Methanol/6mM phosphate 
buffer containing 0.025% heptafluorobutyric acid (HFBA) with the pH adjusted to 6.9 
with triethylamine was used as mobile phase. A 1.2 mL/min flow rate was used, and UV 
detection was carried out at 220 nm. The 20 min time gradient program was as follows : 
0-4 min: 45% Buffer 
4-7 min: 45% to 7% Buffer 
7-14 min: 7% Buffer 
14-17 min: 7% to 45% Buffer 
17-20 min: 45% Buffer 
 
Analytes were eluted out at 4.7 min (codeine), 6.7 min (2-methoxynaphthalene), 
8.4 min (Δ9-THC), and 12.2 min (Cod-THC codrug) using a 20 min gradient time 
program. 
 
The ion-pairing agent HFBA was utilized since it afforded better resolution of 
analyte peaks. Ion pairing agents are ionic compounds that contain a hydrocarbon chain 
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that imparts hydrophobicity such that the resulting analyte ion pair can be better retained 
on the reversed-phase column. Ion-pairing agents are added at concentrations of between 
0.01 to 0.2% w/v. Hydrophobic counter-ions such as trifluoroacetate (TFA) and 
heptafluorobutyrate, in addition to ion-pairing with positively charged solutes also 
increase the affinity of the solute for the hydrophobic stationary phase.  
 
4.3 Results  
 
4.3.1 Assay Validation  
 
The calibration curves were linear over the concentration range of   4-2500 µM for 
Cod-THC, 5-2400 µM for Codeine and 1.0-2200 µM for ∆9-THC with r2 > 0.99 for Cod-
THC, codeine and ∆9-THC respectively (Fig. 4.1). 
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Fig. 4.1 Standard curves for Cod-THC codrug, Δ9-THC and codeine 
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4.3.2 Chemical and enzymatic stability study 
 
 Chemical and enzymatic stability studies on the Cod-THC codrug were carried 
out in vitro. Chemical hydrolysis was examined utilizing buffers at pH 1.3, 5, 7.4 and 9.7, 
and enzymatic hydrolysis was examined in simulated gastric fluid (SGF), simulated 
intestinal fluid (SIF), rat plasma and brain homogenate. Half-life values and the rate 
constant of the hydrolysis of the codrug in different media were obtained from slopes of 
semi-logarithmic plots of codrug concentrations versus time. 
 
The data from the chemical hydrolysis studies at pH 1.3 and in SGF indicates that 
the Cod-THC codrug is stable in these media, and thus is not likely to undergo chemical 
or enzymatic hydrolysis in the stomach when given orally. In fact, no observable 
degradation of the codrug occurred in these media over 8 hours (Figs. 4.2, 4.3). Thus, the 
Cod-THC codrug should pass unhydrolyzed through the stomach after oral 
administration. Additionally, at pHs 5.0, 7.4 and in SIF, no degradation of the codrug was 
observed for 8 hours. Thus, the codrug should be absorbed intact from the intestine and 
reach the systemic circulation as a single molecular entity (Figs. 4.2, 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 Hydrolysis of the Cod-THC codrug at different pHs (non-enzymatic hydrolysis) 
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Fig. 4.3 Hydrolysis of the Cod-THC codrug in different enzymatic solutions 
 
In rat plasma, significant hydrolysis of the Cod-THC codrug was observed and 
the kinetics of codrug disappearance with concomittant codeine and Δ9-THC appearance 
was determined by HPLC-DAD analysis. The disappearance of the Cod-THC codrug was 
correlated with pseudo first order kinetics (Figs. 4.3, 4.4). The same kinetic behavior was 
observed in buffer at pH 9.7 (Figs. 4.2, 4.5). Table 4.2 reports the hydrolytic rate 
constants and half-life values of the codrug obtained by regression analysis from slopes 
of semi-logarithmic plots of concentration versus time. 
 
4.3.3 Stability study in brain homogenate 
 
 The stability study of the Cod-THC codrug in brain homogenate was carried out 
over 8 hrs and samples were analyzed by HPLC–UV assay. The data from the enzymatic 
hydrolysis study in brain homogenate indicates that the Cod-THC codrug is stable in 
brain, and thus is not likely to undergo enzymatic hydrolysis in the brain. In fact, no 
observable degradation of the codrug occurred over 8 hours (Fig. 4.3).  
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Fig. 4.4 Hydrolysis of the Cod-THC codrug in rat plasma 
 
         
 
Table 4.1 Rate constants for the hydrolysis of the Cod-THC codrug in pH 9.7 buffer and 
80% Rat plasma at 37 
o
C 
 
 t1/2 (hr) Kobs (hr-1) 
Rat plasma 2.46 ± 0.11 0.282 ± 0.012 
pH 9.7 19.25 ± 1.21 0.036 ± 0.001 
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                   Fig. 4.5 Hydrolysis of the Cod-THC codrug at pH 9.7 
 
Results of the comprehensive stability study of the Cod-THC codrug in different 
nonenzymatic aqueous buffers and biological media demonstrate that the carbonate ester 
linkage of the codrug is predicted to be stable in the gastrointestinal tract when the 
codrug is administered orally. Hydrolysis of the carbonate ester linkage in 80% rat 
plasma showed that the codrug is hydrolysed and generates the parent drugs, suggesting 
that after oral administration, and absorption from the gastrointestinal tract the codrug 
will generate both parent drugs in the systemic circulation.  Linker design in codrug 
synthesis has to be carried out in a thoughtful way such that the linker is not too 
chemically labile or too stable. Codrugs with labile linkers will not survive the harsh 
conditions of the gastrointestinal tract, and thus will hydrolyze in the gastrointestinal tract 
before the codrug reaches the systemic circulation. Codrugs with very stable linkers may 
reach the systemic circulation, but may not be capable of generating the parent drugs in 
the plasma. Thus the choice of a carbonate ester linkage linking the allylic hydroxyl 
group of codeine and the phenolic group of Δ9-THC was found to be an ideal codrug 
linker design for oral administration. The stability of the Cod-THC codrug in rat brain 
homogenate indicates that the enzymes present in rat brain homogenate are incapable of 
cleaving the codrug into the parent drugs. This study predicts that any codrug entering the 
brain from the systemic circulation will not be transformed into the parent drugs. Thus, if 
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oral administration of the codrug to rats results in the presence of the parent drug 
molecules in brain, then these parent drugs must have entered the brain as the individual 
parent drug molecules from the systemic circulation, and did not originate through 
hydrolysis of the codrug in the brain. 
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Chapter 5 
Pharmacokinetic Analysis of Cod-THC Codrug 
 
5.1 Introduction 
 
Pharmacokinetics is the study of the time course of a drug concentration in 
different body compartments such as plasma, blood, urine, cerebrospinal fluid, and 
tissues, and incorporates the processes of absorption, distribution, metabolism and 
excretion (ADME) after a specific route of administration of a drug (Smith et al., 2001).  
The drug can enter the body in a variety of ways which have already been 
discussed in detail in Chapter 1. Drugs are mostly given orally for reasons of convenience 
and patient compliance. If the drug has been given orally, then it first enters the 
gastrointestinal tract, and gets absorbed through the gastrointestinal mucosal wall into the 
bloodstream. It is then shunted via the portal vein through the liver, where the “first pass 
effect” takes place, and then reaches the systemic circulation. The first-pass effect is a 
phenomenon of drug metabolism whereby the concentration of a drug is greatly reduced 
before it reaches the systemic circulation. It is the fraction of lost drug during the process 
of absorption which mainly takes place in liver and gut wall. Therefore, the oral 
administration of a drug involves an additional absorption step. The percentage of the 
administered dose reaching the circulation as the free drug is termed the bioavailability of 
the drug. The drug then gets distributed to various tissues and organs in the body. The 
extent of this distribution depends on the structural and physicochemical properties of the 
drug. Some drugs may enter the brain and the central nervous system by crossing the 
blood–brain barrier. Finally, the drug will bind to its molecular target, for example, a 
receptor or an ion channel, and exert its desired action. If the drug is injected directly into 
the bloodstream (e.g. by the intravenous route), then it is 100% available for distribution 
to the tissues. But if it is given orally, then its bioavailability will usually be less than 
100% (Smith et al., 2001).  
 
Once the drug is in the bloodstream, a portion of it is available to illicit its 
pharmacodynamic effect; the rest may bind to plasma proteins in an inactive reversible 
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protein-drug complex. Binding to plasma proteins is sometimes advantageous since the 
drug is continuously released from the protein-drug complex and this can result in a 
prolonged drug action (Smith et al., 2001). The unbound drug follows the concentration 
gradient and gets distributed into the peripheral tissues. These tissues contain specific or 
non-specific binding sites. The non-specific binding sites can act as reservoirs for the 
drug. This “total volume of distribution” determines the equilibrium concentration of 
drug after administration of a specific dose.  
 
Pharmacokinetic parameters are derived from the measurement of drug 
concentrations in blood or plasma after administration. The key pharmacokinetic 
parameters are Volume of Distribution (Vd), Clearance (Cl), Absorption, Half-life (t1/2) 
and Oral Bioavailability (F). Their importance for the dose regimen and dose size is 
shown in Fig. 5.1 (van de Waterbeemd and Gifford, 2003).  
 
Fig. 5.1 Pharmacokinetic Parameters and their importance for dose regimen and dose size 
Volume of Distribution (Vd) -- Volume of Distribution is defined as the apparent 
space or volume into which a drug distributes. It is a theoretical concept that connects the 
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administered dose with the actual initial concentration (C0) present in the systemic 
circulation. If the drug is highly lipophilic in nature, then the drug will have a high 
volume of distribution, because the drug specifically or non-specifically binds to tissues 
and stays there. 
 
Vd = Dose/C0 
 
Clearance (Cl) --Clearance of a drug from the body mainly takes place via the 
liver (hepatic clearance or metabolism, and biliary excretion) and the kidney (renal 
excretion).  
 
By plotting the plasma concentration against time, the area under the curve (AUC) relates 
to dose, bioavailability (F) and clearance. 
 
AUC = F x Dose/Cl 
 
Half-life (t1/2) --Half-life is the time taken for the drug concentration in the plasma 
to be reduced by 50%. It is a function of the clearance and volume of distribution, and 
determines how often a drug needs to be administered. 
 
t1/2 = 0.693 Vd/Cl 
 
Intravenous (IV) bolus dosing (i.e, the entire drug dose is given as a rapid 
injection) captures the pure distribution and elimination processes.  
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Fig. 5.2 Concentration versus time curve 
In the “first pass effect” the liver metabolizes the drug into active or inactive 
metabolites, which can then be more easily excreted. Prodrugs are inactive chemical 
entities that get activated only after they are metabolized to the active drug. This is often 
a strategy utilized to improve pharmacokinetic properties and drug ability. Some drugs 
are excreted in the bile and eventually may pass out of the body in the feces, while some 
are filtered by kidney, where a portion undergoes reabsorption, with the remainder being 
excreted in the urine. Smaller amount of drugs are excreted in the tears, breast milk and 
sweat.  
5.1.1 Pharamacokinetic profile of Codeine and ∆9-THC 
 
 There is a continuing need for novel analgesic medications that are able to 
provide high efficacy pain relief while providing more favorable pharmacokinetics and a 
reduction in undesirable side-effects. Several reports indicate the low bioavailability (2 to 
6%) of ∆9-THC after oral administration in rats due to poor absorption. ∆9-THC is also 
biotransformed by the cytochrome P450 enzymes CYP 3A4, CYP 2C9 and CYP 2C11 to 
11-hydroxy-∆9-THC, which contributes to its psychotropic activity, and to the 11-nor-9-
carboxy-THC glucuronide conjugate, an inactive major urinary metabolite (Gustafson et 
al., 2004; McGilveray, 2005). Codeine is mainly metabolized in liver. Approximately 50-
70% of codeine is converted to codeine-6-glucuronide by UGT2B7 and approximately 
10-15% of codeine is N-demethylated to norcodeine by CYP3A4 (Thorn, 2009). 
Codeine-6-glucuronide also binds to the mu opioid receptor similar to codeine. 
Time 
Ln of  
Blood (or  
Plasma)  
Conc. 
Co V = Dose / Co 
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Approximately 10-15% of codeine is N-demethylated to norcodeine by CYP3A4 (Thorn, 
2009). Norcodeine and Codeine-6-glucuronide both have the affinity for the mu opioid 
receptor similar to codeine. Approximately 0-15% of codeine is O-demethylated by 
CYP2D6 to morphine, the most active metabolite, which has 200 fold greater affinity for 
the mu opioid receptor compared to codeine (Thorn, 2009).  
 
Enhancement of the antinociceptive effect of opioids with cannabinoids has been 
previously described in literature (Cichewecz et al, 1999; Cichewecz et al, 2001; 
Cichewecz and McCarthy 2002; Cichewecz and Welch 2003; Cox et al., 2007; Smith et 
al., 2007; Smith et al., 1998; Welch and Eads, 1999; Williams et al., 2008)). These opioid 
and cannabinoid drugs work via opioid and cannabinoid receptors, which are found 
throughout the central and peripheral nervous system. In addition, these two classes of 
drugs produce similar effects on calcium levels and cyclic AMP accumulation through G 
protein-mediated pathways. However, appropriate combination dosing of these active 
agents to afford concentrations of both drugs at the site of action, e.g., the brain or spinal 
column, can be difficult because of their very different physico-chemical and 
pharmacokinetic properties. Therefore, there is a need to devise a way of administering 
opioids and cannabinoids concomitantly to provide a more favorable pharmacokinetic 
profile that will promote optimal synergism. The analytical study of a Cod-THC Codrug 
designed for this purpose has demonstrated chemical stability in gastrointestinal tract and 
susceptibility to hydrolysis in rat plasma to the parent drugs, codeine and Δ9- THC 
(Chapter 3).  To compare the pharmacokinetic profile of the Cod-THC codrug with those 
of the parent drugs (both individually and as a 1:1 physical mixture) after oral 
administration physical mixture, following studies were carried out:   
 
 To determine the pharmacokinetics of Cod-THC codrug at three different doses 
(5, 10, 20 mg/kg) and to determine the pharmacokinetics codeine, and Δ9-THC 
after oral administration of an equimolar physical mixture dose (4.9 mg/kg 
codeine + 5.1 mg/kg  Δ9-THC) of the two parent drugs in the rat.  
 To evaluate the relative ability of the Cod-THC codrug (10 mg/kg dose) and a 1:1 
physical mixture of codeine and Δ9 –THC (4.9 mg/kg codeine + 5.1 mg/kg  Δ9-
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THC) to deliver codeine and Δ9-THC to the plasma and brain after oral 
administration in the rat.   
 
5.2 Materials and Methods 
 
5.2.1 Chemicals and reagents 
 
The Cod-THC codrug and Δ9-THC were synthesized in the laboratory (see 
Chapter 2 for details). The chemicals used in this study were of HPLC grade or 
equivalent quality. Acetonitrile and potassium chloride were obtained from Thermo 
Fisher Scientific (Pittsburgh, PA). Heparin sodium injection, 10,000 USP units/ml, was 
purchased from Baxter Healthcare Corporation (Deerfield, IL). Nembutal sodium 
(pentobarbital sodium injection, USP) was obtained from Abbott Laboratories (North 
Chicago, IL).  
 
5.2.2 Animals 
 
 All procedures involving animals were performed in compliance with the 
guidelines of the University of Kentucky Institutional Animal Care and Use Committee 
established by the National Institutes of Health’s Guide for the Care and Use of 
Laboratory Animals (1996). Male Sprague-Dawley rats (200–250 g) were obtained from 
Harlan (Indianapolis, IN) and housed two per cage with ad libitum access to food and 
water in the Division of Laboratory Animal Resources at the University of Kentucky 
College of Pharmacy. Body weights at the time of dosing were 300-360 g. Rats were 
anesthetized with pentobarbital (40 mg/kg i.p.) and surgically implanted with jugular and 
femoral vein cannulas for i.v. drug dosing and blood sampling, respectively. For the first 
3 to 4 days after surgery, the rats were observed for signs of infection at the surgical sites, 
yellowing of hair and hair texture, presence of blood around the eyes or nose, indications 
of loss of appetite, and decreased or absent fecal activity before the start of  i.v. dosing.  
 
5.2.3 Instrumentation 
120 
 
 
Samples were analyzed for analyte-specific (640.359 m/z to 282.261 m/z, Cod-
THC; 315.2 m/z to 193.1 m/z, Δ9-THC; 300.2 m/z to 215.2 m/z, codeine; 286 m/z to 201 
m/z morphine) and internal standard-specific (342.4 m/z to 324.2 m/z, naltrexone) 
transitions by LC/MS/MS utilizing reverse-phase chromatography and positive-mode 
ionization. The instrumentation consisted of a Varian LC system (ProStar 210 pumps, 
Prostar 410 autoinjector) connected through an ESI source to a Varian 1200L triple 
quadrupole mass spectrometer with all components controlled by a Varian MS 
Workstation version 6.42. Individual analyte-dependent ESI-(+)-MS/MS parameters were 
optimized for signal intensity. 
  
5.2.4 HPLC and mass spectrometric conditions 
 
 Individual analyte-dependent ESI-(+)-MS/MS parameters were optimized for 
signal intensity. These optimized parameters were subsequently used in the analysis of 
biological samples (CE = 32, 19, 20.5, 16.5, 10.2V for Cod-THC, Δ9-THC, codeine, 
morphine and naltrexone, respectively). Briefly, 10 µL of the biological sample was 
injected onto a guard column protected (Nova-Pak® C18; 3.9 x 20 mm; 4µ) Nova-Pak® 
C18 analytical column (3.9 x 150 mm; 4 um). Analytes were eluted at 8.09 min 
(morphine), 10.02 min (codeine), 10.22 min (naltrexone), 14.33 min (Cod-THC), and 
21.37 min (Δ9-THC) using water: acetonitrile (82:18, containing 0.04 % HFBA) (Solvent 
A): acetonitrile (Solvent B) gradient and a 0.3 mL/min flow rate. The 33 min gradient 
program began with 97:3 Solvents A: B for 3 min followed by a 5.3 min linear ramp to 
5:95 solvents A: B. This percentage was held constant for 14 min, and then returned to 
97:3 solvents A:B over a 3 min linear ramp; it was then held at 97:3 solvents A:B for an 
additional 6 min. Argon was used as a collision gas  at 2.0 m Torr, and nitrogen used as a 
drying gas at 300 oC. The needle voltage was 5000V, the shield voltage was 600V, and 
the capillary voltage was 40V. Independent plasma and brain calibration curves for Cod-
THC, codeine, morphine and Δ9-THC were generated from plots of analyte concentration 
and analyte: naltrexone peak area ratios.  
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5.2.5 Plasma Pharmacokinetics 
 
Cod-THC codrug solution was prepared in 15% PEG-400 solution in saline and 
filtered through a 0.2-µm filter. Groups of rats (n=3) were then injected with either 5, 10, 
20 mg/kg p.o. or 1 mg/kg i.v. via the jugular vein. Doses and route of administration were 
chosen on the bases of studies evaluating the analgesic effect of Cod-THC codrug. Blood 
samples (0.2 mL) were obtained at 1, 5, 10, 15, 30, 45, 60, 120, 180 min after i.v. dosing 
and at 15 min, 30 min, 1, 2, 4, 5, 7 and 8 hrs after oral dosing. The withdrawn blood was 
replaced with heparinized saline (0.2 mL). Blood samples were centrifuged at 1200 g for 
15 min, and the plasma was separarted. The separated plasma was frozen immediately on 
dry-ice and stored at −80°C prior to analysis. To compare the pharmacokinetics of the 
codrug with an equimolar physical mixture, 4.9 mg/kg of codeine and 5.1 mg/kg of Δ9-
THC were mixed together and administered orally to rats. This dose of physical mixture 
was chosen based on the same molar proportion of codeine and Δ9-THC in the 10 mg/kg 
codrug dose.  
 
5.2.6 Standard Curve and Quality Control Validation Solutions  
 
Stock solutions of Cod-THC, codeine, Δ9-THC and internal standard (naltrexone) 
were prepared in methanol. Two stock solutions were prepared; one for generating the 
standard curve, and a second one for quality control (QC) and method validation. A 
standard curve with eight points was prepared for the analysis of unknown samples. 
Standard curve samples were prepared by spiking blank plasma with Cod-THC, codeine, 
or Δ9-THC working solutions. Calibration curves were obtained using quadratic least-
squares regression of AUC ratio (analyte peak AUC/internal standard peak AUC) versus 
drug concentrations. The amount of codrug, or parent drug, was then determined. Three 
quality control samples with different concentrations were prepared to check the 
sensitivity of the instrument. The three concentrations chosen were: one towards the 
higher end of the standard curve concentrations, one towards the middle, and the third 
one towards the lower end of the standard curve concentrations. Standard curves for 
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analyzing brain samples were constructed in a similar way using brain homogenate. In 
brain homogenate, a morphine standard curve was also generated. 
 
5.2.7 Extraction procedure 
 
 To isolate Cod-THC, codeine, and Δ9-THC from plasma or brain samples, 50 µL 
of plasma/brain tissue was transferred to polypropylene tubes to which 10 µl of working 
internal standard solution was added followed by vortexing for 1 min. The samples were 
then centrifuged for 15 min at 8000 rpm.  The supernatant was transferred into silylated 
micro-serts and evaporated to dryness under nitrogen gas at 37°C. Following drying, the 
residue was dissolved in 80 µl of mobile phase by vortexing for 1min; 10 µl of the 
sample was then injected into the LC-MS/MS unit.  
 
5.2.8 Brain Uptake Study  
 
Studies were performed to determine the concentration of codrug/parent drugs 
present in brain after oral doses of 10 and 20 mg/kg of Cod-THC codrug. These doses 
were chosen based on their assessment in the tail-flick pain model. Cod-THC codrug 
solution was prepared in 15% PEG-400 solution in saline and filtered through a 0.2-µm 
filter. Noncatheterized male Sprague-Dawley rats (300-360) were assigned randomly to 
one of five time points (n =3 per group) for the 10 mg/kg Cod-THC codrug dose and to 
one of two time points (n=3 per group) for the 20 mg/kg dose. Individual rats were 
euthanized at 0.5, 1, 1.5, 2, 2.5 hrs after p.o. administration of the 10 mg/kg Cod-THC 
codrug and at 2 and 2.5 hrs after p.o. administration of the 20 mg/kg Cod-THC codrug. 
The brain was quickly removed, cleaned of surrounding tissue and veins, washed, 
weighed, and homogenized (3 volumes of 1.15% KCl/g brain tissue) for 2 min in a tissue 
homogenizer (Bio-Homogenizer M133/1281-0; Biospec Products, Inc., Barlesville, OK). 
Brain homogenate (4 ml) was mixed with an equal volume of acetonitrile and centrifuged 
at 1200g and 37°C for 5 min. The supernatant was separated and evaporated to dryness 
under a stream of nitrogen. The residue was reconstituted in 80 µL of HPLC mobile 
phase. After decapitation, blood from the trunk of each rat at the time of euthanasia was 
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also collected and centrifuged at 1200g and 37°C for 5 min to obtain matching 
brain/plasma samples. The plasma samples (50 µL ml) were extracted with 6 volumes of 
acetonitrile and centrifuged at 1200 g for 15 min at 37°C. The supernatant was separated 
and evaporated to dryness under a stream of nitrogen, and the resulting residue was 
reconstituted with 80 µL of mobile phase. The same protocol was followed for the 
physical mixture of codeine and Δ9-THC. To compare with the 10 mg/kg Cod-THC 
codrug dose, 4.9 mg/kg of codeine and 5.1 mg/kg of Δ9-THC was utilized as a physical 
mixture. Again, the time-concentration curve for this physical mixture was generated in a 
similar way to that for the codrug.  
 
5.2.9 Assay Validation  
 
Blank plasma samples were extracted and analyzed by reverse phase HPLC for 
potential interfering peaks  within  the  range of  the  retention  time for  Cod-THC, 
codeine, morphine, Δ9-THC and  the  internal  standard, naltrexone. The extraction 
efficiency was determined by spiking Cod-THC, codeine, and Δ9-THC at concentrations 
of 25 and 100 ng/ml into blank plasma, and comparing peak AUCs of the extracted and 
unextracted standards at the same concentrations. This was done to find the difference 
between the concentrations of extracted and unextracted samples. 
 
5.2.10 Pharmacokinetic Analysis  
 
The plasma pharmacokinetic parameters for the Cod-THC codrug in the rat were 
determined after both p.o. and i.v. administration. Data were analyzed with a standard 
noncompartmental model using the program WinNonlin Professional (version 5.2; 
Pharsight Corporation, Mountain View, CA). Both Cmax and Tmax were determined. The 
AUC0–t for the plasma concentration-time profile was determined using the linear-
trapezoidal method (Whittaker and Robinson, 1967). AUC 0–∞ was calculated as AUC0–t 
+ Ct/k, where Ct is the last measurable concentration of drug. The terminal half-life (t1/2) 
was calculated by dividing 0.693 by the terminal rate constant (k) obtained from the fitted 
concentration-time data.  
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5.3 Results 
 
  Morphine, codeine, naltrexone, Δ9-THC, and the Cod-THC codrug 
chromatograms are shown in Fig. 5.3. Morphine had the lowest retention time (8.09 min) 
followed by codeine (10.02 min), naltexone (10.22 min), Cod-THC (14.33 min) and Δ9-
THC (21.37 min).  
 
5.3.1 Assay Validation  
 
The calibration curves for the Cod-THC codrug were linear over the 
concentration range of 0.67-343.04 ng/mL , and for codeine and Δ9-THC were linear over 
the concentration range 1.45-371.2 ng/mL and 1.45-371.2 ng/mL, respectively, in rat 
plasma, with correlation coefficients r2 of > 0.99 for Cod-THC, codeine and Δ9-THC 
(Fig. 5.4). The LLOQ was established at 0.67, 1.45 and 1.45 ng/mL for Cod-THC codrug, 
codeine and Δ9-THC, respectively.  
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Fig. 5.3 Morphine, codeine, naltrexone, Cod-THC codrug and Δ9-THC Chromatograms  
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(a) 
(b) 
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Fig. 5.4 Calibration curves for codeine (a), Δ9-THC (b) and Cod-THC codrug (c) in rat 
plasma  
 
 
The calibration curves for Cod-THC, codeine, Δ9-THC and morphine were 
generated in rat plasma (from trunk blood) and also in rat brain homogenate (Figs. 5.5, 
5.6). At the time of the brain homogenate study, the calibration curves for plasma (from 
trunk blood) were generated again to compare the concentration of the parent drugs in 
brain and plasma. The calibration curves generated in brain homogenate were linear over 
the concentration range 0.52-266.2 ng/mL for the Cod-THC codrug, linear over the 
concentration range 0.61-312.3 ng/mL for codeine, and linear over the concentration 
range 0.86-440.3 ng/mL for Δ9-THC and 6.13-196.2 ng/mL for morphine in rat plasma, 
with correlation coefficients r2 > 0.99 for Cod-THC, codeine, Δ9-THC and morphine 
(Fig. 5.4). Fig. 5.7 shows the three chromatograms of morphine with three different 
(c) 
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concentrations (3000, 300 and 3 ng/mL). The morphine peak was detectable only up to 3 
ng/mL.  
 
 
 
 
 
 
(a) 
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(c) 
(b) 
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Fig. 5.5 Calibration Curves for codeine (a), Δ9-THC (b), Cod-THC codrug (c) and 
morphine (d) in rat plasma (trunk plasma) 
 
5.3.2 Dose-response curve analysis for the Cod-THC codrug in plasma samples 
 
  The mean concentration versus time profiles for 5, 10 and 20 mg/kg doses of 
Cod-THC codrug after oral administration are shown in Fig. 5.8. As can be seen, in all 
the three doses, the Cod-THC codrug is hydrolyzed in the plasma to release the parent 
drugs. The hydrolysis is not complete, as codrug can be seen along with the parent drugs 
at all time points. These data also show a prolonged release of the parent drugs from the 
codrug over time. The release of the parent drugs from the codrug occurs in an equimolar 
ratio. At any time point in the time course, the codrug concentration is lower than that of 
(d) 
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either of the parent drugs, indicating the presence of mainly parent drugs compared to 
codrug.  
 
Since the codrug is being hydrolyzed in the plasma and releasing parent drugs in 
1:1 ratio, this suggests that there is likely no stable intermediate codrug fragment being 
formed, and even if such an intermediate is forming, it is transient and is getting 
hydrolyzed very quickly to release the parent drugs concomittently. The pharmacokinetic 
parameters for Cod-THC, codeine and Δ9-THC for the 5, 10, and 20 mg/kg doses are 
summarized in Table 5.1.  Following oral administration of the 5 and 10 mg/kg doses of 
Cod-THC codrug, plasma levels of codeine and Δ9-THC reached Cmax within 1 hr. For 
the 20 mg/kg dose there was a slight plateau from 2-4 hrs. This might be due to plasma 
enzyme saturation, which would decrease the rate of hydrolysis of the codrug. The data 
clearly show a dose-dependent relationship, since the AUC for the codrug, as well as for 
the parent drugs, increased linearly with increasing dose of codrug.  
 
 
 
 
(a) 
132 
 
 
 
 
(b) 
(c) 
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Fig. 5.6 Calibration Curves for codeine, Δ9-THC, Cod-THC codrug and 
 morphine in brain homogenate  
 
 
(d) 
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Fig. 5.7 Morphine peaks generated from different concentrations (3000, 300 and 3 ng/mL 
from the top) using slightly different LC-MS/MS method (0.05% of HFBA was added to 
both aqueous and organic solvents as compared to 0.025% in the previously described 
method).  
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Fig. 5.8 Plasma concentration vs. time curve after oral administration of Cod-THC 
codrug (5, 10 and 20 mg/kg doses)  
5 mg/kg Cod-THC codrug dose 
10 mg/kg Cod-THC codrug 
 
20 mg/kg Cod-THC codrug 
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Table 5.1 (a) Pharmacokinetic parameters for the Cod-THC codrug, codeine and Δ9-THC 
after 5, 10, 20 mg/kg oral dosing  
 
 Dose AUC  T max  C max  T 1/2  
  (hr* pmol/mL) (hr) (pmol/mL) (hr) 
      
 5 mg/kg 90.9 ± 17.4 1 ± 0.1 14.16 ± 4.64 4.24 ± 0.33 
Codrug  10 mg/kg 199.7 ± 29.3 2 ± 0.1 24.4 ± 2.96 4.43 ± 0.25 
(Actual) 20 mg/kg 326.5 ± 37.4 4 ± 0.2 31.95 ± 6.14 4.57 ± 0.39 
      
 5 mg/kg 281.7 ± 22.8 1 ± 0.1 39.8 ± 2.32 2.3 ± 0.37 
∆9- THC 10 mg/kg 375.3 ± 18.2 1 ± 0.2 48.1 ± 3.18 4.0 ± 0.46 
 20 mg/kg 474.2 ± 25.6 2.5 ± 0.3 56.4 ± 3.41 4.9 ± 0.44 
      
 5 mg/kg 218.0 ± 19.6 1 ± 0.1 40.46 ± 2.75 2.4 ± 0.29 
Codeine 10 mg/kg 318.0 ± 23.8 1 ± 0.3 49.17 ± 3.41 2.5 ± 0.38 
 20 mg/kg 374.2 ± 28.3 3 ± 0.2 57.39 ± 3. 97 4.1 ± 0.42 
 
 
Table 5.1 (b) Calculated clearance values for the Cod-THC codrug, codeine and Δ9-THC 
 
  
Clearance  
(mL/min) 
Cod-THC Codrug 35.3 
Codeine 55.6 
∆9-THC 28.5 
 
 
5.3.3 Codrug and physical mixture data comparison after oral administration 
 
 The mean concentration versus time profile for the 10 mg/kg dose of the physical 
mixture (i.e. 4.9 mg/kg codeine and 5.1 mg/kg Δ9-THC) after oral administration is 
shown in Fig. 5.9. For comparison, the 10 mg/kg Cod-THC codrug graph is also 
displayed in the same figure. The plasma concentrations of codeine and Δ9-THC are 
much higher after codrug administration compared to the plasma concentrations of these 
drugs after administration of an equimolar physical mixture. The parent drugs are clearly 
released from the codrug in 1:1 ratio, while administration of the physical mixture does 
not afford equimolar concentrations of codeine and Δ9-THC in plasma. This is likely due 
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to the different pharmacokinetic profiles of the two parent drugs and to the different 
pharmacokinetic profile of the Cod-THC codrug. The parent drugs are also present in 
plasma for longer period of time after oral administration of the codrug, probably due to 
the sustained release of the parent drugs from codrug in the plasma. When the 
pharmacokinetic parameters of an equimolar physical mixture of codeine and Δ9-THC 
were calculated and compared with that of an equimolar dose of codrug after oral 
administration, a significantly higher AUC for codeine and Δ9-THC was observed from 
the codrug than from the physical mixture of the parent drugs.  
 
 The oral bioavailability of codeine and Δ9-THC can be calculated from the AUC 
values from the oral dose (4.9 mg/kg codeine + 5.1 mg/kg Δ9-THC) and the AUC from 
the i.v. dose of the physical mixture (0.49 mg/kg codeine + 0.51 mg/kg Δ9-THC). The 
calculated bioavailability for codeine was 2.9 ± 1.4 % and the bioavailability for Δ9-THC 
was 3.0 ± 1.8 %.  
 
 Calculation of the oral bioavailability of the codrug is not straight-forward 
because of the time-dependent hydrolysis of the codrug to the parent compounds in the 
plasma. Thus, two bioavailability values for the codrug can be calculated, i.e. the “actual” 
codrug bioavailability, and the “total” codrug bioavailability. The actual codrug 
bioavailability is based on the amount of actual codrug present in the plasma; whereas the 
total codrug bioavailability is calculated assuming no hydrolysis of the codrug has taken 
place in the plasma. The total bioavailability value represents an approximation of the 
total amount of the codrug entering the systemic circulation after oral dosing. The actual 
codrug bioavailability was calculated to be 7.7 ± 3.8 %, and the total codrug 
bioavailability was found to be 21.1 ± 7.9 %. Since the total codrug bioavailability is 
much higher than the bioavailabilities of either of the parent drugs after oral 
administration of the physical mixture, this shows that more of parent drugs can be 
delivered orally in the form of the codrug than as a physical mixture. It should be noted 
that the total codrug bioavailabilty value may be underestimated, since the clearance 
parameters are not taken into account for the parent drugs (shown in Table 5.1 (b)). 
138 
 
Certainly, the data clearly indicates that the codrug has a superior pharmacokinetic 
profile when compared to the physical mixture of the two parent drugs. 
 
 
 
 
 
Fig. 5.9 Physical mixture of Codeine (4.9 mg) and Δ9-THC (5.1 mg) (a); Codrug 10 
mg/kg (b)  
 
(a) 
(b) 
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Fig. 5.10 Concentration vs. Time profile for Cod-THC (10 mg/kg dose) (a) and Physical 
mixture (Cod 4.9 mg/kg + ∆9-THC 5.1 mg/kg) (b) in brain after oral dosing 
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5.3.4 Brain Uptake Study Results 
 
 After oral administration of 10 mg/kg dose of the Cod-THC codrug, brain 
samples were analysed at different time points (0, 0.5, 1, 1.5, 2, and 2.5 hrs). The results 
of the analysis of the brain homogenate samples showed the presence of only the parent 
drugs; no codrug was present in brain at any time point measured after oral dosing of the 
Cod-THC codrug.  
 
Fig. 5.10 shows the time versus concentration profiles for the Cod-THC codrug 
(10 mg/kg) and the physical mixture (4.9 mg/kg codeine and 5.1 mg/kg THC) after oral 
administration. The concentration of codeine and ∆9-THC is much higher in brain after 
oral administration of the Cod-THC codrug as compared to the brain concentrations of 
these drugs after oral administration of the physical mixture. The concentrations of 
codeine and ∆9-THC in the brain reach a maximum at two hours after oral administration; 
it is important to note that tmax is same for both codeine and ∆9-THC. This correlates with 
the study of the codrug in rat tail-flick pain model. In the case of the physical mixture, the 
∆9-THC concentration is significantly higher than the codeine concentration in brain after 
oral administration. This might be attributable to the higher plasma concentration of ∆9-
THC compared to codeine in plasma samples after oral administration of the physical 
mixture.  
 
Thus from the pharmacokinetic data, it can be concluded that Cod-THC codrug is 
much more efficient in terms of delivering higher concentrations of the two parent drugs 
in both plasma and brain when compared to the equimolar physical mixture of the two 
parent drugs. This also proves that combining two drugs with different physicochemical 
and pharmacokinetic profiles into a single chemical entity can improve the plasma and 
brain bioavailabilities of the two parent drugs. It is also noticeable that oral 
administration of the codrug produces the two parent drugs in molar ratio while the 
physical mixture fails to do that. 
 
Copyright © Harpreet Dhooper 2010 
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Chapter 6 
Summary 
 
There is a continuing need for analgesic medications that are able to provide high 
efficacy pain relief while providing more favorable pharmacokinetics and reducing the 
possibility of undesirable side effects. Enhancement of the analgesic effect of opioids 
with cannabinoids has been previously described (Cichewicz et al., 1999). These opioid 
and cannabinoid drugs work via opioid and cannabinoid receptors, which are found 
throughout the central and peripheral nervous system. Synergy between ∆9-THC and 
opioids is well documented in the literature (Bloom and Dewey, 1978; Cichewicz and 
McCarthy, 2002). In addition, these two classes of drugs produce similar effects on 
calcium levels and cyclic AMP accumulation through G protein-mediated pathways. 
However, appropriate dosing of these active agents to the site of action, e.g., the brain or 
spinal column, can be difficult because of their differential pharmacokinetics. Therefore, 
in the present dissertation, a codrug strategy is presented for orally administering opioids 
and cannabinoids concomitantly to provide a more favorable pharmacokinetic and 
analgesic profile than would be attainable by administering equimolar amounts of the 
parent drugs as a physical mixture. 
 
Codrugs are designed to overcome various barriers to drug formulation and 
delivery, such as poor or extreme aqueous solubility, chemical instability, insufficient 
absorption after oral administration, rapid pre-systemic metabolism, inadequate brain 
penetration, toxicity and local irritation. The first chapter in this dissertation demonstrates 
the usefulness of the codrug strategy by discussing several reported examples. The 
codrug strategy is very useful when the physico-chemical and/or pharmacokinetic 
properties of two synergistic drugs are not favorable for delivery as a physical mixture, 
but can be improved by chemical combination of the two drugs. 
 
A series of novel codrugs obtained by chemical conjugation of the opiate drug 
codeine with ∆9-THC, cannabidiol, and abn-cannabidiol, and of the opiate prodrug 3-O-
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acetylmorphine with ∆9-THC, utilizing a carbonate linker moiety, were successfully 
synthesized. Before commencing the synthetic work with the expensive opiate and 
cannabinoid controlled substances, coupling reactions were initially carried out with 
model compounds, or chemical mimics of the drug molecules, in order to optimize the 
desired coupling chemistry. p-Nitrophenylchloroformate, which has been described in the 
literature as a useful reagent for the formation of unsymmetrical carbonates and 
carbamates (Anderson and McGregor, 1957) was found to be a useful reagent in these 
subsequent model coupling reactions. In the current work, an opiate was initially reacted 
with p-nitrophenylchloroformate to form the carbonate conjugate of the opiate and p-
nitrophenol. This intermediate was then reacted with different cannabinoids to form the 
carbonate ester conjugate (codrug) of the opiate and the cannabinoid.  In this second step, 
the good leaving group property of the p-nitrophenol is advantageous in the selective 
formation of the desired unsymmetrical carbonate ester. 
 
Marketed for p.o. administration as dronabinol (Marinol®), Δ9-THC is a schedule 
II drug currently used as an appetite stimulant in acquired immunodeficiency syndrome-
wasting patients, and as an anti-emetic for cancer chemotherapy when given orally. 
Although high doses of Δ9-THC are analgesic, they can be accompanied by side effects, 
such as anxiety, dry mouth or euphoria/dysphoria. The opiate codeine is commonly given 
p.o., primarily to ease pain. However, the continued administration of codeine can lead to 
tolerance, which can ultimately reduce the analgesic effect of the drug, necessitating the 
administration of high and potentially harmful doses to achieve effective pain control. 
Also, high doses of codeine can have undesirable side effects such as respiratory 
depression, constipation, nausea and vomiting. Given that mixtures of Δ9-THC and 
codeine are synergistic in the rat tail-flick test for antinociception (Williams et al., 2006), 
we hypothesized that when given in the form of codrug, the administration of codeine 
and Δ9-THC would have improved pharmacokinetics that would enhance the efficacy of 
codeine in managing pain. Also, since codeine shows little or no effect on neuropathic 
pain, we further hypothesized that a Cod-THC codrug would also exhibit an analgesic 
effect in neuropathic pain models. Thus, we investigated the effect of the Cod-THC 
codrug after oral administration in nociceptive and neuropathic pain models utilizing tail-
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flick and chronic constriction injury pain models in the rat. The oral efficacies of each of 
the parent drugs, codeine and Δ9-THC were also compared with the Cod-THC codrug as 
pain modulators in the above pain models to determine their relative effectiveness. In 
both pain models, the codrug showed better effectiveness, as well as more prolonged pain 
management properties, when compared to the parent drugs. ED50 values for the Cod-
THC codrug were much lower in tail flick and CCI models as compared to codeine. Cod-
CBD codrug was also analysed for its analgesic effect using tail-flick test.  
 
The Cod-THC codrug was initially evaluated for its stability in buffers ranging 
from pH 1 to pH 9, as well as in simulated gastric and intestinal fluids (SGF and SIF, 
respectively), and in rat plasma and brain homogenate. SGF simulates stomach fluid and 
incorporates acidic and enzymatic hydrolysis conditions. SIF mimics the intestinal 
enzymes. The stability of the codrug was determined in the following media utilizing an 
HPLC-UV assay. 
 
• pH : Aqueous buffers (37 ºC, pH 1-9) 
• Gastrointestinal tract : Simulated gastric fluid (USP, 37 ºC) 
• Gastrointestinal tract : Simulated intestinal fluid (USP, 37 ºC) 
• Plasma : Rat plasma (37 ºC) 
• Brain homogenate (37 oC) 
 
The codrug was found to have a favorable drug stability profile for oral 
administration, being stable in aqueous solutions over a wide range of physiologically 
relevant pHs from 1 to 7.4, and was also stable in SGF, SIF and rat brain homogenate. In 
rat plasma, the codrug was hydrolyzed to the two parent drugs, codeine and Δ9-THC with 
a rate constant of 0.282 hr-1. 
 
Results of the comprehensive stability study of the Cod-THC codrug in different 
non-enzymatic aqueous buffers and in biological media demonstrate that the carbonate 
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ester linkage of the codrug is predicted to be stable in the gastrointestinal tract when the 
codrug is administered orally. Hydrolysis of the carbonate ester linkage in 80% rat 
plasma showed that the codrug is enzymatically cleaved to generate the parent durgs, 
suggesting that after oral administration, and absorption from the gastrointestinal tract the 
codrug will generate both parent drugs in the systemic circulation (plasma).  Linker 
design in the codrug synthesis has to be carried out in a thoughtful way such that the 
linker is not too chemically labile or too stable. Codrugs with labile linkers will not 
survive the harsh conditions of the gastrointestinal tract, and thus will hydrolyze in the 
gastrointestinal tract before the codrug reaches the systemic circulation. Codrugs with 
very stable linkers may reach the systemic circulation, but may not be capable of 
generating the parent drugs in the plasma. Thus, the choice of a carbonate ester linkage 
linking the allylic hydroxyl group of codeine and the phenolic group of Δ9-THC was 
found to be an ideal codrug linker design for oral administration. The stability of the Cod-
Δ9-THC codrug in rat brain homogenate indicates that the enzymes present in rat brain 
homogenate are incapable of cleaving the codrug into the parent drugs. Therefore, this 
study predicts that any codrug entering the brain from the systemic circulation will not be 
transformed into the parent drugs. Thus, if oral administration of the codrug to rats results 
in the presence of the parent drug molecules in brain, then these parent drugs must have 
entered the brain as the individual parent drug molecules from the systemic circulation, 
and did not originate through hydrolysis of the codrug in the brain. 
 
The pharmacokinetic profile of the Cod-THC codrug was evaluated in the rat after 
oral administration and compared with the pharmacokinetic profile of the physical 
mixture of the parent drugs Several groups have reported the low bioavailability of THC 
(2 to 6%) and codeine (4 to 8%) after oral administration in rats, due to poor absorption 
from the gastrointestinal tract (Chiang and Barnett, 1984; Shah and Mason, 1990). 
Therefore, rat plasma and brain concentrations, of the Cod-THC codrug were determined 
after oral and i.v. administration utilizing an LC-MS/MS analytical methodology.These 
properties were compared with those obtained after oral administration of an equimolar 
physical mixture of the two parent drugs, codeine and Δ9-THC. 
 
145 
 
 The plasma concentrations of codeine and Δ9-THC were found to be much higher 
after oral administration of the codrug in the rat, compared to plasma concentrations of 
these drugs after oral administration of the equimolar physical mixture of the two parent 
drugs. The parent drugs were clearly released from the codrug molecule in 1:1 ratio in 
plasma, while administration of the physical mixture did not afford equimolar 
concentrations of codeine and Δ9-THC in the plasma. This is likely due to the different 
pharmacokinetic profiles of the two parent drugs, and to the different pharmacokinetic 
profile of the Cod-THC codrug. Also, the parent drugs were present in plasma for a 
longer period of time after oral administration of codrug, probably due to the sustained 
release of the parent drugs from the codrug in the plasma. The actual codrug 
bioavailability was calculated to be 7.7 ± 3.8 %, and the total codrug bioavailability was 
found to be 21.1 ± 7.9 %. Since the total codrug bioavailability is much higher than the 
bioavailabilities of either of the parent drugs after oral administration of the physical 
mixture, this shows that more of parent drugs can be delivered orally in the form of the 
codrug than as a physical mixture. It should be noted that the total codrug bioavailabilty 
value may be underestimated, since the clearance parameters are not taken into account 
for the parent drug. But still, the data clearly indicates the superior pharmacokinetic 
profile of a codrug as compared to the physical mixture of the two parent drugs. 
 
The time versus concentration profiles for the Cod-THC codrug and the 
equimolar physical mixture were generated to determine the concentrations of the parent 
drugs in the brainafter oral administration. The Cod-THC codrug was not detected in the 
brain, which indicates that the hydrolysis of the codrug is taking place in the plasma, and 
then the parent drugs cross the blood-brain-barrier to exert their effect. The 
concentrations of codeine and Δ9-THC were much higher in brain after oral 
administration of the Cod-THC codrug as compared to brain concentrations of these 
drugs after oral administration of the physical mixture. The concentrations of codeine and 
Δ9-THC in the brain reach a maximum at two hours after oral administration. This 
correlates with the study of the codrug in the pain models. The Δ9-THC concentration 
was found to be higher than the codeine concentration in brain after oral administration of 
the physical mixture while the concentration of codeine was higher in the brain after oral 
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administration of the codrug. This may be attributed to the higher plasma concentration 
of Δ9-THC compared to codeine in plasma samples after oral administration of the 
physical mixture. 
 
The above data indicate that oral administration of a codeine-Δ9-THC codrug 
could be useful therapeutic delivery sssrategy to enhance the pain modulating properties 
of codeine. Thus, if extrapolatable to humans, following opioid administration in the 
form of an opioid-THC codrug, patients might require a lower dose of opioid, need fewer 
administrations of the opioid to control pain, and subsequently experience fewer side 
effects. Not only that, in cancer chemotherapy, where opioids show little or no effect in 
managing chemotherapeutically-induced neuropathic pain, the codrug approach of 
combining an opioid with a THC may be a better substitute for codeine alone, since it 
would be effective in managing a broader spectrum of pain. 
 
Thus, this study proves the hypothesis that a codrug of an opiate and a 
cannabinoid can be synthesized, which is stable in gastrointestinal tract and shows a 
superior pharmacokinetic profile when compared to a physical mixture of the two parent 
drugs that make up the codrug. Also, an enhanced pharmacological effect of the codrug 
can be achieved compared to that of the two parent drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Harpreet Dhooper 2010 
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